```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1         Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2         "Ask CAS" for self-help around the clock
 NEWS  3  DEC 05  CASREACT(R) - Over 10 million reactions available
 NEWS  4  DEC 14  2006 MeSH terms loaded in MEDLINE/LMEDLINE
 NEWS  5  DEC 14  2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
 NEWS  6  DEC 14  CA/CAplus to be enhanced with updated IPC codes
 NEWS  7  DEC 21  IPC search and display fields enhanced in CA/CAplus with the
                  IPC reform
 NEWS  8  DEC 23  New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
                  USPAT2
 NEWS  9  JAN 13  IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
 NEWS 10  JAN 13  New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
                  INPADOC
 NEWS 11  JAN 17  Pre-1988 INPI data added to MARPAT
 NEWS 12  JAN 17  IPC 8 in the WPI family of databases including WPIFV

 NEWS EXPRESS  JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
               V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
               http://download.cas.org/express/v8.0-Discover/

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 20:41:08 ON 29 JAN 2006

=>
Uploading
```

```
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 20:41:23 ON 29 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    27 JAN 2006  HIGHEST RN 872965-93-0
DICTIONARY FILE UPDATES:   27 JAN 2006  HIGHEST RN 872965-93-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*********************************************************************
*                                                                   *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                   *
*********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10684990.str
```





```
chain nodes :
10  12
ring nodes :
1  2  3  4  5  6  7  8  9
chain bonds :
6-12  9-10
ring bonds :
1-2  1-7  2-3  3-4  4-8  5-6  5-9  6-7  7-8  8-9
exact/norm bonds :
5-6  5-9  6-12  8-9  9-10
exact bonds :
6-7
normalized bonds :
1-2  1-7  2-3  3-4  4-8  7-8
isolated ring systems :
containing 1 :


G1:CH2,CH,C(O)CH3

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:CLASS
12:CLASS



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```



G1 CH2,CH,C(O)CH3

```
Structure attributes must be viewed using STN Express query preparation.


=> s l1
SAMPLE SEARCH INITIATED 20:41:39 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     3073 TO ITERATE

 65.1% PROCESSED     2000 ITERATIONS                                 33 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:        58136 TO    64784
PROJECTED ANSWERS:             587 TO     1441

L2            33 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 20:41:46 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    60849 TO ITERATE

100.0% PROCESSED    60849 ITERATIONS                               1073 ANSWERS
SEARCH TIME: 00.00.01

L3          1073 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\10684990a.str
```





```
chain nodes :
12  13  14  15  16  17  18  19  20  21
ring nodes :
1  2  3  4  5  6  7  8  9
chain bonds :
6-12  9-17  12-13  12-14  14-15  14-16  17-18  18-19  18-21  19-20
ring bonds :
1-2  1-7  2-3  3-4  4-8  5-6  5-9  6-7  7-8  8-9
exact/norm bonds :
5-6  5-9  8-9  9-17  12-13  18-21
exact bonds :
6-7  6-12  12-14  14-15  14-16  17-18  18-19  19-20
normalized bonds :
1-2  1-7  2-3  3-4  4-8  7-8
isolated ring systems :
containing 1 :


G1:CH2,CH,C(O)CH3

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  12:CLASS
13:CLASS  14:CLASS  15:CLASS  16:CLASS  17:CLASS  18:CLASS  19:CLASS  20:CLASS
21:CLASS



L4       STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4                STR
```



```
G1 CH2,CH,C(O)CH3


Structure attributes must be viewed using STN Express query preparation.


=> s l4
SAMPLE SEARCH INITIATED 20:46:01 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        2 TO ITERATE

100.0% PROCESSED        2 ITERATIONS                            0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            2 TO      124
PROJECTED ANSWERS:               0 TO        0

L5           0 SEA SSS SAM L4

=> s l4 sss full
FULL SEARCH INITIATED 20:46:07 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      120 TO ITERATE

100.0% PROCESSED      120 ITERATIONS                            3 ANSWERS
SEARCH TIME: 00.00.01

L6           3 SEA SSS FUL L4

=> FIL HCAPLUS
COST IN U.S. DOLLARS                                 SINCE FILE     TOTAL
                                                          ENTRY   SESSION
FULL ESTIMATED COST                                      336.52    336.73

FILE 'HCAPLUS' ENTERED AT 20:46:19 ON 29 JAN 2006
```

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

```
FILE COVERS 1907 - 29 Jan 2006  VOL 144 ISS 6
FILE LAST UPDATED: 27 Jan 2006  (20060127/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s l3
L7          252 L3

=> s l6
L8            3 L6

=> s l7 and ocular
          15845 OCULAR
             22 OCULARS
          15863 OCULAR
                  (OCULAR OR OCULARS)
L9            7 L7 AND OCULAR

=> s l7 and p/dt
        5106170 P/DT
L10         144 L7 AND P/DT

=> s l10 and us/pc
        1505654 US/PC
L11          93 L10 AND US/PC

=> s l11 and py<=2003
       23835053 PY<=2003
L12          71 L11 AND PY<=2003

=> s l12 and thu
            145 THU
        2291055 THUS
        2291184 THU
                  (THU OR THUS)
L13          38 L12 AND THU

=> s l13 and hypertension
          76261 HYPERTENSION
             97 HYPERTENSIONS
          76281 HYPERTENSION
```

```
                (HYPERTENSION OR HYPERTENSIONS)
L14          3 L13 AND HYPERTENSION

=> d 18 ibib abs hitstr tot

L8   ANSWER 1 OF 3  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2005:1289303  HCAPLUS
DOCUMENT NUMBER:          144:36257
TITLE:                    Preparation of substituted benzoic acid and analogs as
                          EP4 receptor agonists for treatment of glaucoma and
                          related diseases
INVENTOR(S):              Belley, Michel; Colucci, John; Girard, Mario; Han,
                          Yongxin; Lacombe, Patrick
PATENT ASSIGNEE(S):       Merck Frosst Canada Ltd., Can.
SOURCE:                   PCT Int. Appl., 80 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE         APPLICATION NO.        DATE
     ---------------     ----   --------     --------------------   --------
     WO 2005116010        A1    20051208     WO 2005-CA773          20050520
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
             NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
             SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
             ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:                   US 2004-574653P     P  20040526
GI
```



I



II

AB Title compds. I [Z1 = CW1, N; W1, X, W = H, amino, halo; Y = H, halo, alkoxy, etc.; R1-2 = H, halo, alkyl, etc.; R3 = R1, OH, etc.; Q = carboxy, tetrazolyl, etc.; Ar1 = Ph, pyridinyl, thienyl, etc.; Ar2 = benzoxadiazolyl, Ph, pyridyl, etc.] are prepared For instance, II is prepared in 4 steps from 3-bromo-5-chloro-2-hydroxybenzaldehyde, 3-methoxybenzyl bromide, 4-bromobenzonitrile and azidotributyltin. II has a binding affinity for the EP4 subtype of prostaglandin E2 receptor of 2.0 nM. I are useful for the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient. I are also used for mediating the bone modeling and remodeling processes of osteoblasts and osteoclasts.

IT **691899-65-7**, 1-(3-Isobutyryl-6-methoxy-1H-indazol-1-yl)-3,3-dimethylbutan-2-one **691901-12-9**, 1-(3-Isobutyryl-6-methoxy-1H-indazol-1-yl)butan-2-one
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(agonists of EP4 receptor subtype of PGE2 receptors and their use for treatment of glaucoma, other conditions and for mediating bone modeling and remodeling processes of osteoblasts and osteoclasts)

RN 691899-65-7 HCAPLUS

CN 2-Butanone, 1-[6-methoxy-3-(2-methyl-1-oxopropyl)-1H-indazol-1-yl]-3,3-dimethyl- (9CI) (CA INDEX NAME)



RN 691901-12-9 HCAPLUS
CN 2-Butanone, 1-[6-methoxy-3-(2-methyl-1-oxopropyl)-1H-indazol-1-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1106800 HCAPLUS
DOCUMENT NUMBER: 143:387049
TITLE: Preparation of disubstituted piperidinones, oxazinanones, thiazinanones, and morpholinones as EP4 receptor agonist for treatment of ocular and bone disorders
INVENTOR(S): Billot, Xavier; Colucci, John; Han, Yongxin; Wilson, Marie-claire; Young, Robert N.
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 30 pp.; Division of U.S. Ser. No. 297,257.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2005227969	A1	2005~~1013~~	US 2005-146992		20050607
US 2004198701	A1	2004~~1007~~	US 2004-797257		20040310
PRIORITY APPLN. INFO.:			US 2004-797257	A3	20040310
			US 2003-457700P	P	20030326

OTHER SOURCE(S): MARPAT 143:387049

AB This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compds. of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts. In particular, this invention relates to a series of 1,6-disubstituted piperidin-2-one, 3,4-disubstituted 1,3-oxazinan-2-one, 3,4-disubstituted 1,3-thiazinan-2-one, and 4,5-disubstituted morpholin-3-one derivs. The compds. of the invention are optionally formulated with other therapeutic agents useful in treating eye disorders or in stimulating bone formation such as β-adrenergic blocking agents, carbonic anhydrase inhibitors, and bisphosphonates. Preparation schemes for the compds. of the invention are disclosed.

IT **691899-65-7**, 1-(3-Isobutyryl-6-methoxy-1H-indazol-1-yl)-3,3-dimethylbutan-2-one **691901-12-9**, 1-(3-Isobutyryl-6-methoxy-1H-indazol-1-yl)butan-2-one
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(addnl. therapeutic agent; preparation of disubstituted piperidinones, oxazinanones, thiazinanones, and morpholinones as EP4 receptor agonists for treatment of ocular and bone disorders)

RN 691899-65-7 HCAPLUS
CN 2-Butanone, 1-[6-methoxy-3-(2-methyl-1-oxopropyl)-1H-indazol-1-yl]-3,3-dimethyl- (9CI) (CA INDEX NAME)



RN 691901-12-9 HCAPLUS
CN 2-Butanone, 1-[6-methoxy-3-(2-methyl-1-oxopropyl)-1H-indazol-1-yl]- (9CI) (CA INDEX NAME)



L8 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:414645 HCAPLUS
DOCUMENT NUMBER: 140:423670
TITLE: Preparation of indazoles as potent potassium channel blockers for treating ocular hypertension
INVENTOR(S): Doherty, James B.; Chen, Meng-Hsin; Liu, Luping; Natarajan, Swaminathan R.; Tynebor, Robert M.

```
PATENT ASSIGNEE(S):       USA
SOURCE:                   U.S. Pat. Appl. Publ., 30 pp.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND    DATE          APPLICATION NO.          DATE
     ---------------     ----    --------      --------------------     --------
     US 2004097575        A1     20040520      US 2003-684990           20031014
     CA 2505086           AA     20040527      CA 2003-2505086          20031104
     WO 2004043932        A1     20040527      WO 2003-US35078          20031104
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK,
             LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
             OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     WO 2004043933        A1     20040527      WO 2003-US35080          20031104
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK,
             LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
             OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     EP 1562909           A1     20050817      EP 2003-781747           20031104
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     BR 2003016040        A      20050913      BR 2003-16040            20031104
     NO 2005002751        A      20050607      NO 2005-2751             20050607
PRIORITY APPLN. INFO.:                         US 2002-424808P      P   20021108
                                               US 2003-500091P      P   20030904
                                               WO 2003-US35078      W   20031104
                                               WO 2003-US35080      A   20031104
OTHER SOURCE(S):          MARPAT 140:423670
GI
```



I



II

AB The title compds. [I; R = H, alkyl; X = (CHR7)p, (CHR7)pCO; Y = CO(CH2)n, CH2, CH(OR); Q = CH, C(alkyl); R2 = H, alkyl, OH, etc.; R3 = H, alkyl, heterocyclyl, etc.; QR2R3 = 3-10 membered carbocyclic or heterocyclic ring, OR; R4, R5 = H, alkoxy, OH, etc.; R6 = H, alkyl, (CH2)n(aryl), etc.; R7 = H, alkyl, (CH2)nCO2R, (CH2)nNR2; n = 0-3; p = 0-3], useful for the treatment of glaucoma and other conditions which leads to elevated intraocular pressure in the eye of a patient, were prepared Thus, reacting 3-benzoyl-6-methoxyindazole (preparation given) with 1-bromopinacolone in the presence of NaH in DMF afforded II. The IC50 for block of maxi-K channels for the compds. I ranged from about 0.5 nM to about 10 μM. This invention also relates to the use of compds. I to provide a neuroprotective effect to the eye of mammalian species, particularly humans. Ophthalmic compns. comprising the compound I is claimed.

IT **691899-65-7P 691901-12-9P 691901-45-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indazoles as potent potassium channel blockers for treating ocular hypertension)

RN 691899-65-7 HCAPLUS
CN 2-Butanone, 1-[6-methoxy-3-(2-methyl-1-oxopropyl)-1H-indazol-1-yl]-3,3-dimethyl- (9CI) (CA INDEX NAME)



RN 691901-12-9 HCAPLUS
CN 2-Butanone, 1-[6-methoxy-3-(2-methyl-1-oxopropyl)-1H-indazol-1-yl]- (9CI) (CA INDEX NAME)



RN 691901-45-8 HCAPLUS
CN 2-Butanone, 1-[3-(2,2-dimethyl-1-oxopropyl)-6-methoxy-1H-indazol-1-yl]-3,3-dimethyl- (9CI) (CA INDEX NAME)



```
=> d l9 ibib abs hitstr tot

L9   ANSWER 1 OF 7  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2005:1106800  HCAPLUS
DOCUMENT NUMBER:          143:387049
TITLE:                    Preparation of disubstituted piperidinones,
                          oxazinanones, thiazinanones, and morpholinones as EP4
                          receptor agonist for treatment of ocular and
                          bone disorders
INVENTOR(S):              Billot, Xavier; Colucci, John; Han, Yongxin; Wilson,
                          Marie-claire; Young, Robert N.
PATENT ASSIGNEE(S):       Can.
SOURCE:                   U.S. Pat. Appl. Publ., 30 pp., Division of U.S. Ser.
                          No. 297,257.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.          KIND    DATE          APPLICATION NO.          DATE
     ---------------     ----    --------      --------------------     --------
     US 2005227969        A1     ~~20051013~~      US 2005-146992           20050607
     US 2004198701        A1     20041007      US 2004-797257           20040310
PRIORITY APPLN. INFO.:                         US 2004-797257       A3  20040310
                                               US 2003-457700P      P   20030326
OTHER SOURCE(S):          MARPAT 143:387049
AB   This invention relates to potent selective agonists of the EP4 subtype of
     prostaglandin E2 receptors, their use or a formulation thereof in the
     treatment of glaucoma and other conditions, which are related to elevated
     intraocular pressure in the eye of a patient.  This invention further
     relates to the use of the compds. of this invention for mediating the bone
     modeling and remodeling processes of the osteoblasts and osteoclasts.  In
     particular, this invention relates to a series of 1,6-disubstituted
     piperidin-2-one, 3,4-disubstituted 1,3-oxazinan-2-one, 3,4-disubstituted
     1,3-thiazinan-2-one, and 4,5-disubstituted morpholin-3-one derivs.  The
     compds. of the invention are optionally formulated with other therapeutic
     agents useful in treating eye disorders or in stimulating bone formation
     such as β-adrenergic blocking agents, carbonic anhydrase inhibitors,
     and bisphosphonates.  Preparation schemes for the compds. of the invention are
     disclosed.
IT   362512-14-9, 1-(2-Aminopropyl)-3-methyl-1H-indazol-6-ol fumarate
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (addnl. therapeutic agent; preparation of disubstituted piperidinones,
        oxazinanones, thiazinanones, and morpholinones as EP4 receptor agonists
        for treatment of ocular and bone disorders)
RN    362512-14-9   HCAPLUS
CN    1H-Indazol-6-ol, 1-(2-aminopropyl)-3-methyl-, (2E)-2-butenedioate (1:1)
      (salt) (9CI)  (CA INDEX NAME)

      CM    1

      CRN   362512-13-8
      CMF   C11 H15 N3 O
```



```
      CM    2

      CRN   110-17-8
      CMF   C4 H4 O4

Double bond geometry as shown.
```



```
L9   ANSWER 2 OF 7  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2005:260033  HCAPLUS
DOCUMENT NUMBER:          142:336355
TITLE:                    Preparation of indazole derivatives as potassium
                          channel blockers for treating ocular
                          hypertension
INVENTOR(S):              Chen, Meng Hsin; Doherty, James B.; Liu, Luping;
                          Natarajan, Swaminathan; Tynebor, Robert M.
PATENT ASSIGNEE(S):       Merck & Co., Inc., USA
SOURCE:                   PCT Int. Appl., 49 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND  DATE       APPLICATION NO.         DATE
     ---------------     ----  --------   --------------------    --------
     WO 2005026128        A1   20050324   WO 2004-US28266         20040831
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
```

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

PRIORITY APPLN. INFO.:   US 2003-500095P   P 20030904

OTHER SOURCE(S):   MARPAT 142:336355

GI



I



II

AB Indazoles I [R, R1 = H, (un)substituted OH, NH2, CO2H, SO3H, OP(O)(OH)2, CF3, NO2, CN, halogen; R2 = H, (un)substituted OH, alkyl, cycloalkyl, heterocyclyl, NH2, CO2H, aryl; R3 = H, (un)substituted alkyl, cycloalkyl, heterocyclyl, CO2H, aryl, NH2, CONH2, alkoxy, SO2H, acyl, CF3, NO2, CN, halogen; QR2R3 = cyclic, heterocyclic; Q = (un)substituted CH2; X = bond, (un)substituted alkylene, oxoalkylene; X1 = bond, NH, O; X2 = bond, alkylene, haloalkylene; Y = CO, CO(CH2)n, CH2, (un)substituted CH(OH); Y1 = (un)substituted aryl, heterocyclyl; Z = (un)substituted (CH2)nP(O)(OH)2; n = 0-3] were prepared for use in treating **ocular** hypertension with IC50 for blocking of the maxi-K channel of 10-500 nM. Thus, the indazole II was prepared from 2,4-F(MeO)C6H3CHO by cyclization with hydrazine to 6-methoxy-3-methyl-1H-indazole which was N-protected, brominated, and converted to aldehyde, followed by Grignard reaction with 4-Me3CSiMe2OCH2C6H4I, deblocking, reaction with BrCH2COCMe3 and phosphorylation.

IT **691900-63-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indazole derivs. as potassium channel blockers for treating **ocular** hypertension)

RN 691900-63-7 HCAPLUS

CN 1H-Indazole-3-carboxaldehyde, 1-(diethoxymethyl)-6-methoxy- (9CI) (CA

```
     INDEX NAME)
```



```
REFERENCE COUNT:          3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9   ANSWER 3 OF 7  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2005:259877  HCAPLUS
DOCUMENT NUMBER:          142:336354
TITLE:                    Preparation of indazole derivatives as potassium
                          channel blockers for treating ocular
                          hypertension
INVENTOR(S):              Chen, Meng Hsin; Doherty, James B.; Liu, Luping;
                          Natarajan, Swaminathan; Tynebor, Robert M.
PATENT ASSIGNEE(S):       Merck & Co., Inc., USA
SOURCE:                   PCT Int. Appl., 53 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.            KIND   DATE       APPLICATION NO.        DATE
     ---------------       ----   --------   --------------------   --------
     WO 2005025568          A1    20050324   WO 2004-US28351        20040831
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW:  BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
PRIORITY APPLN. INFO.:                       US 2003-500090P     P  20030904
OTHER SOURCE(S):          MARPAT 142:336354
GI
```



I



II

AB Indazoles I [R, R1 = H, (un)substituted OH, CO2H, NH2, SO3H, alkyl, CF3, NO2, CN, halogen; R2 = H, OH, (un)substituted alkyl, alkenyl, cycloalkyl, heterocyclyl, NH2, CO2H, aryl; R3 = H, (un)substituted alkyl, cycloalkyl, heterocyclyl, CO2H, aryl, NH2, CONH2, SO2H, SO2NH2, acyl, CF3, NO2, CN, halogen; QR2R3 = cyclic, heterocyclic; Q = N, O; X = bond, alkylene, oxoalkylene; X1 = bond, NH, O; X2 = bond, (un)substituted alkylene; Y = CO(CH2)n, CH2, (un)substituted CH(OH); n = 0-3; Y1 = (un)substituted aryl, heterocyclyl; Z = (un)substituted (CH2)nOP(O)(OH)2] were prepared as potassium channel blockers for the treatment of glaucoma and other conditions which lead to elevated intraocular pressure. I have IC50 for inhibition of the maxi-K channel of 10-500 nM. Thus, the indazole II was prepared from 6-methoxy-1H-indazole-3-carboxaldehyde, 5-iodo-2-chloropyridine, BrCH2CONBu2, and HOCH2CH2OH, followed by phosphorylation.

IT **691900-63-7P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of indazole derivs. as potassium channel blockers for treating **ocular** hypertension)

RN 691900-63-7 HCAPLUS

CN 1H-Indazole-3-carboxaldehyde, 1-(diethoxymethyl)-6-methoxy- (9CI) (CA INDEX NAME)



```
REFERENCE COUNT:          1      THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
                                 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9   ANSWER 4 OF 7  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2005:29163  HCAPLUS
DOCUMENT NUMBER:          142:134596
TITLE:                    A preparation of imidazole derivatives, useful for the
                          treatment of ocular hypertension
INVENTOR(S):              Chen, Meng Hsin; Doherty, James B.; Liu, Luping;
                          Natarajan, Swaminathan R.; Shen, Dong-Ming; Shu, Min
PATENT ASSIGNEE(S):       Merck & Co., Inc., USA
SOURCE:                   PCT Int. Appl., 73 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND    DATE          APPLICATION NO.         DATE
     ---------------     ----    --------      --------------------    --------
     WO 2005002520        A2     20050113      WO 2004-US20752         20040625
     WO 2005002520        A3     20050331
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
PRIORITY APPLN. INFO.:                         US 2003-483996P      P  20030701
OTHER SOURCE(S):          MARPAT 142:134596
GI
```



I



II



III

AB The invention relates to a preparation of imidazole derivs. of formula I [wherein: M, Y, and Z are independently selected from CH or N; W is (CH2)0-3-[alkyl/alkoxy/(hetero)cycloalkyl], CO2H, or CH2C(O)NH-(H/alkyl/heterocyclyl), etc.; Y is (CH2)0-6, C(O)(CH2)0-3, SO2, or O, etc.; R1 is H, alkyl, (hetero)aryl, or CO2H, etc.; R2 and R3 are independently selected from H, alkoxy, OH, alkyl, or SO3H, etc.], useful for the treatment of **ocular** hypertension. The invention compds. are potent potassium channel blockers, useful in the treatment of glaucoma and other conditions which leads to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compds. to provide a neuroprotective effect to the eye of mammalian species, particularly humans. For instance, benzimidazole derivative II was prepared via N-ethanoylation of benzimidazole derivative III by Me bromoacetate, hydrolysis of the obtained Me benzimidazolylacetate derivative, and subsequent amidation by di-(iso-amyl)amine. The prepared compds. were tested on high-conductance calcium-activated potassium channels (electrophysiol. assays) and showed Ki values from 0.01 nM to 10 μM.

IT **362512-14-9**, 1-(2-Aminopropyl)-3-methyl-1H-indazol-6-ol fumarate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(5-HT2 receptor agonist, drug component; preparation of imidazole derivs. useful for the treatment of **ocular** hypertension)

RN 362512-14-9 HCAPLUS

CN 1H-Indazol-6-ol, 1-(2-aminopropyl)-3-methyl-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 362512-13-8
CMF C11 H15 N3 O



```
     CM   2

     CRN  110-17-8
     CMF  C4 H4 O4

Double bond geometry as shown.
```



```
L9   ANSWER 5 OF 7  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2004:430692  HCAPLUS
DOCUMENT NUMBER:          141:7107
TITLE:                    Preparation of 1H-indazoles as K channel blockers for
                          use in ophthalmic compositions for treating
                          ocular hypertension
INVENTOR(S):              Doherty, James B.; Chen, Meng-Hsin; Liu, Luping;
                          Natarajan, Swaminathan R.; Shen, Dong-Ming; Tynebor,
                          Robert M.
PATENT ASSIGNEE(S):       Merck & Co., Inc., USA
SOURCE:                   PCT Int. Appl., 80 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE         APPLICATION NO.        DATE
     ---------------     ----   --------     --------------------   --------
     WO 2004043354        A2    20040527     WO 2003-US34959        20031104
     WO 2004043354        A3    20040826
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK,
             LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
             OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2505127           AA    20040527     CA 2003-2505127        20031104
     EP 1581503           A2    20051005     EP 2003-781722         20031104
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     US 2006020000        A1    20060126     US 2005-530840         20050408
```

PRIORITY APPLN. INFO.: US 2002-424790P P 20021108
US 2003-500094P P 20030904
WO 2003-US34959 W 20031104

OTHER SOURCE(S): MARPAT 141:7107

GI



I



II

AB This invention relates to the preparation and use of title compds. I [wherein X = (CHR7)p, (CHR7)pCO; Y = CO(CH2)n, CH2, CH(OR); Q = N or O, wherein R2 is absent when Q = O; R = H or alkyl; R2 = H, OH, (CH2)nO(CH2)mOR, CO2R, NR2, or (un)substituted alkyl, alkenyl, alkoxy(alkyl), thioalkyl, cycloalkyl(alkyl), heterocyclyl(alkyl), aryl(alkyl); R3 = H, NO2, CN, halo, (CH2)nCO2R, (CH2)SO2R, (CH2)nSO2NR2, or (un)substituted alkyl, cycloalkyl(alkyl), heterocyclyl(alkyl), aryl(alkyl), alkoxy(alkyl), carbamoyl(alkyl), (CH2)nNH2; R4 and R5 = independently H, alkoxy, OH, alkyl, acyl, CO2R, SO3H, O(CH2)nNR2, OPO3H2, CF3, NR2, NO2, CN, halo, etc.; R6 = H, CO2R, COCO2R, or (un)substituted alkyl, aryl(alkyl), NH2, heterocyclyl(alkyl), aryloxy, cycloalkyl(alkyl), etc.; R7 = H, alkyl, (CH2)nCO2R, (CH2)nNR2; m = 0-3; n = 0-3; p = 0-3; and pharmaceutically acceptable salts, enantiomers, diastereomers, or mixts. thereof] and pharmaceutical compns. comprising them as potent K channel blockers for the treatment of glaucoma and other conditions which leads to elevated intraocular pressure in the eye of a patient (no data). This invention also relates to the use of I to provide a neuroprotective effect to the eye of mammalian species, particularly humans (no data). For example, 3-benzoyl-6-methoxy-1H-indazole (preparation given) was N-alkylated with Me bromoacetate in the presence of NaH in DMF and the product hydrolyzed using LiOH in THF to afford II. Compds. of the invention inhibited maxi-K channels in TsA-201 cells with IC50 values < 20µM in a fluorescence assay and blocked the activity of maxi-K channels in human non-pigmented ciliary epithelial cells with IC50 values < 20µM in an electrophysiol. study.

IT **362512-14-9**, 1-(2-Aminopropyl)-3-methyl-1H-indazol-6-ol fumarate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy agent; preparation of 1H-indazoles as K channel blockers for use in ophthalmic compns. for treating **ocular** hypertension)

RN 362512-14-9 HCAPLUS

CN 1H-Indazol-6-ol, 1-(2-aminopropyl)-3-methyl-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 362512-13-8
CMF C11 H15 N3 O



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



IT **691900-63-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of 1H-indazoles as K channel blockers for use in ophthalmic compns. for treating **ocular** hypertension)
RN 691900-63-7 HCAPLUS
CN 1H-Indazole-3-carboxaldehyde, 1-(diethoxymethyl)-6-methoxy- (9CI) (CA INDEX NAME)



L9 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:414645 HCAPLUS
DOCUMENT NUMBER: 140:423670
TITLE: Preparation of indazoles as potent potassium channel blockers for treating **ocular** hypertension
INVENTOR(S): Doherty, James B.; Chen, Meng-Hsin; Liu, Luping; Natarajan, Swaminathan R.; Tynebor, Robert M.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 30 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

```
     PATENT NO.          KIND    DATE          APPLICATION NO.        DATE
     ---------------     ----    --------      --------------------   --------
     US 2004097575        A1     20040520      US 2003-684990         20031014
     CA 2505086           AA     20040527      CA 2003-2505086        20031104
     WO 2004043932        A1     20040527      WO 2003-US35078        20031104
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK,
             LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
             OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     WO 2004043933        A1     20040527      WO 2003-US35080        20031104
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK,
             LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
             OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     EP 1562909           A1     20050817      EP 2003-781747         20031104
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     BR 2003016040        A      20050913      BR 2003-16040          20031104
     NO 2005002751        A      20050607      NO 2005-2751           20050607
PRIORITY APPLN. INFO.:                         US 2002-424808P     P  20021108
                                               US 2003-500091P     P  20030904
                                               WO 2003-US35078     W  20031104
                                               WO 2003-US35080     A  20031104
OTHER SOURCE(S):         MARPAT 140:423670
GI
```



I



II

```
AB   The title compds. [I; R = H, alkyl; X = (CHR7)p, (CHR7)pCO; Y = CO(CH2)n,
     CH2, CH(OR); Q = CH, C(alkyl); R2 = H, alkyl, OH, etc.; R3 = H, alkyl,
     heterocyclyl, etc.; QR2R3 = 3-10 membered carbocyclic or heterocyclic
     ring, OR; R4, R5 = H, alkoxy, OH, etc.; R6 = H, alkyl, (CH2)n(aryl), etc.;
     R7 = H, alkyl, (CH2)nCO2R, (CH2)nNR2; n = 0-3; p = 0-3], useful for the
     treatment of glaucoma and other conditions which leads to elevated
```

intraocular pressure in the eye of a patient, were prepared Thus, reacting 3-benzoyl-6-methoxyindazole (preparation given) with 1-bromopinacolone in the presence of NaH in DMF afforded II. The IC50 for block of maxi-K channels for the compds. I ranged from about 0.5 nM to about 10 μM. This invention also relates to the use of compds. I to provide a neuroprotective effect to the eye of mammalian species, particularly humans. Ophthalmic compns. comprising the compound I is claimed.

IT **362512-14-9**, 1-(2-Aminopropyl)-3-methyl-1H-indazol-6-ol fumarate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-administration; preparation of indazoles as potent potassium channel blockers for treating **ocular** hypertension in combination with other agents)

RN 362512-14-9 HCAPLUS

CN 1H-Indazol-6-ol, 1-(2-aminopropyl)-3-methyl-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 362512-13-8
CMF C11 H15 N3 O



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



IT **691900-63-7P 691900-98-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indazoles as potent potassium channel blockers for treating **ocular** hypertension)

RN 691900-63-7 HCAPLUS

CN 1H-Indazole-3-carboxaldehyde, 1-(diethoxymethyl)-6-methoxy- (9CI) (CA INDEX NAME)



```
RN    691900-98-8   HCAPLUS
CN    2-Butanone, 1-[3-[[4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]phenyl
      ]hydroxymethyl]-6-methoxy-1H-indazol-1-yl]-3,3-dimethyl- (9CI)   (CA INDEX
      NAME)
```



```
L9   ANSWER 7 OF 7  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2004:203664  HCAPLUS
DOCUMENT NUMBER:          140:253553
TITLE:                    Preparation of oxazolidin-2-one and thiazolidin-2-one
                          derivatives for use as prostaglandin E2 receptor
                          EP4-subtype agonists
INVENTOR(S):              Han, Yongxin; Colucci, John; Billot, Xavier; Wilson,
                          Marie-Claire; Young, Robert
PATENT ASSIGNEE(S):       Merck Frosst Canada & Co., Can.
SOURCE:                   PCT Int. Appl., 66 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE          APPLICATION NO.         DATE
     ---------------     ----   --------      --------------------    --------
     WO 2004019938        A1    20040311      WO 2003-CA1306          20030825
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,
             LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG,
             PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
             TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
```

CA 2495917 AA 20040311 CA 2003-2495917 20030825
EP 1545517 A1 20050629 EP 2003-790594 20030825
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRIORITY APPLN. INFO.: US 2002-406530P P 20020828
WO 2003-CA1306 W 20030825
OTHER SOURCE(S): MARPAT 140:253553
GI



I

AB This invention relates to compds. of formula (I) [X = O, S; Y1 = CH2CH2, CH:CH, cyclopropane-1,2-diyl; Y = CO, CH(OH); A, W = a bond, C1-6 alkylene optionally substituted with 1, 2, 3, or 4 halogen atoms; Z = O, S, cyclopropane-1,2-diyl, CH2, HC:H, C.tplbond.C, each disubstituted aryl or heteroaryl ring; R2 = C1-6 alkyl, provided that R2 is not n-pentyl, (CH2)0-8-C6-10 aryl, (CH2)0-8-C5-10 heteroaryl, (CH2)0-8-C3-10 heterocycloalkyl, (CH2)0-8-C3-8cycloalkyl, O-C1-10-oalkyl, O-C6-10aryl, O-C5-10heteroaryl, O-C5-10heterocycloalkyl, O-C3-10cycloalkyl wherein aryl, heteroaryl, heterocycloalkyl, and cycloalkyl are optionally substituted; R3, R4 = H, halogen, C1-6 alkyl; or R3 and R4, together with the carbon atom to which they are attached, form a C3-7 cycloalkyl ring; R5 = H, OH, CH2OH, C1-6 alkoxy, NHPO2R6, NHR9, NHSO2R8, NR6R7; R6, R7 = H, C1-6 alkyl; R8 = H, C6-10 aryl, C1-4 alkyl; R9 = acyl, sulfonyl] are prepared These compds. are potent selective agonists of the EP4 subtype of prostaglandin E2 receptors. Also disclosed are their use for a medicament in the treatment of conditions which are related to elevated intraocular pressure in the eye of a patient by (1) treating **ocular** hypertension, glaucoma, macular edema, or macular degeneration, (2) increasing retinal and optic nerve head blood velocity, (3) increasing retinal and optic nerve tension, (4) providing a neuroprotective effect, or (5) treating dry eyes.

IT **362512-14-9**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy; preparation of oxazolidinone and thiazolidinone derivs. as prostaglandin E2 receptor EP4-subtype agonists in treatment of conditions related to elevated intraocular pressure in eye)
RN 362512-14-9 HCAPLUS
CN 1H-Indazol-6-ol, 1-(2-aminopropyl)-3-methyl-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 362512-13-8
CMF C11 H15 N3 O



```
     CM   2

     CRN  110-17-8
     CMF  C4 H4 O4

Double bond geometry as shown.
```



```
REFERENCE COUNT:          4      THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
                                 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d l14 ibib abs hitstr tot

L14  ANSWER 1 OF 3  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2002:449674  HCAPLUS
DOCUMENT NUMBER:          137:33321
TITLE:                    Preparation of indazolyl-substituted pyrroline
                          compounds as kinase inhibitors for treating or
                          ameliorating kinase-mediated disorders
INVENTOR(S):              Zhang, Han-Cheng; Maryanoff, Bruce; Conway, Bruce;
                          White, Kimberly; Ye, Hong; Hecker, Leonard R.;
                          McComsey, David F.
PATENT ASSIGNEE(S):       Ortho-McNeil Pharmaceutical, Inc., USA
SOURCE:                   PCT Int. Appl., 148 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND    DATE          APPLICATION NO.        DATE
     ---------------     ----    --------      --------------------   --------
     WO 2002046183        A2     20020613      WO 2001-US47689        20011206 <--
     WO 2002046183        A3     20020906
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
             UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2431166           AA     20020613      CA 2001-2431166        20011206 <--
     AU 2002030727        A5     20020618   AU 2002-30727          20011206 <--
     US 2003055097        A1     20030320   US 2001-13181          20011206 <--
     US 6849643           B2     20050201
     EP 1362047           A2     20031119   EP 2001-990971         20011206 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     JP 2004515499        T2     20040527   JP 2002-547921         20011206
     BR 2001016468        A      20040629   BR 2001-16468          20011206
     NZ 526356            A      20050225   NZ 2001-526356         20011206
     NO 2003002625        A      20030805   NO 2003-2625           20030610 <--
     ZA 2003005239        A      20041007   ZA 2003-5239           20030707
     US 2004259928        A1     20041223   US 2004-885373         20040706 <--
     US 2005004202        A1     20050106   US 2004-909537         20040802 <--
PRIORITY APPLN. INFO.:                      US 2000-254166P     P  20001208
                                            US 2001-13181       A3 20011206
                                            WO 2001-US47689     W  20011206
OTHER SOURCE(S):         MARPAT 137:33321
GI
```



I

AB   Novel indazolyl-substituted pyrroline compds. of formula [I; R1, R2 = H, C1-5 alkyl, C2-8 alkenyl, or C2-8 alkynyl (wherein alkyl, alkenyl and alkynyl are optionally substituted), -C(O)-C1-8 alkyl, -C(O)-aryl-C(O)-O-C1-8 alkyl, -C(O)-O-aryl, -C(O)-NH-C1-8 alkyl, -C(O)-NH-aryl-C(O)-N-[C1-8 alkyl]2, -SO2-C1-8 alkyl, -SO2-aryl, aryl, heteroaryl (wherein aryl and heteroaryl are optionally substituted); X = N, CR5; R3, R4 = H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 alkoxy, C(O)H-C(O)-C1-8 alkyl, CO2H, C(O)-O-C1-8 alkyl, CONH2, C(:NH)NH2, C(O)-NH-C1-8 alkyl, C(O)-N(C1-8 alkyl)2, SH, S-C1-8 alkyl, SO2-C1-8 alkyl, SO2NH2, SO2-NH-C1-8 alkyl, SO2-N(C1-8 alkyl)2, N-(un)substituted amino or amino-C1-8 alkyl cyano, halo, (halo)1-3-C1-8 alkyl, (halo)1-3-C1-8 alkoxy, hydroxy, hydroxy-C1-8 alkyl, nitro, aryl, -C1-8 alkylaryl, heteroaryl -C1-8 alkylheteroaryl; Y, Z = O, S, (H,OH), (H,H); with the proviso that one of Y and Z is O and the other is selected from the group consisting of O, S, (H,OH) and (H,H); R5 = hydrogen, halogen, (un)substituted C1-8 alkyl, C2-8 alkenyl, or C2-8 alkynyl] and pharmaceutically acceptable salts thereof are prepared These compds. are selective inhibitors of kinase or dual inhibitors of at least two kinases selected from protein kinase C, glycogen synthetase kinase-3, protein kinase C α, protein kinase C β-II, protein kinase C γ, glycogen synthetase kinase-3β, for treating or ameliorating kinase, and dual-kinase mediated disorders. They are useful for treating or ameliorating a kinase-mediated disorders selected from cardiovascular diseases, diabetes, diabetes-associated disorders, inflammatory diseases, immunol. disorders, dermatol. disorders, oncol. disorders and CNS disorders. **Thus**, 2-[1-(3-pyridyl)indol-3-yl]-2-oxoacetic acid Me ester (700 mg, 2.5 mmol) and

2-[1-(3-dimethylaminopropyl)-1H-indazol-3-yl]acetamide (546 mg, 2.1 mmol) were combined in dry THF (10 mL) under argon and cooled with an ice bath as 1 M potassium t-butoxide in THF (8.4 mL, 8.4 mmol) was added with stirring over a 20 min period. After 1 h, the reaction was quenched in an ice bath by adding 12 N HCl (3.5 mL, 42 mmol) slowly over a 3 min period to give, after purification by flash column chromatog., 3-[1-[3-(dimethylamino)propyl]-1H-indazol-3-yl]-4-[1-(3-pyridinyl)-1H-indol-3-yl]-1H-pyrrole-2,5-dione (II). II showed IC50 of 0.007, 0.124, and 0.213 μM against protein kinase C isoforms β-II, α, and γ, resp.

IT **436159-87-4P**, 2-[1-(3-Dimethylaminopropyl)-1H-indazol-3-yl]acetamide **436160-16-6P**, 2-(1-Glycidyl-5-chloro-1H-indazol-3-yl)acetic acid **436160-17-7P**, 2-[1-[2-Hydroxy-3-(dimethylamino)propyl]-5-chloro-1H-indazol-3-yl]acetamide **436161-11-4P**, 2-[1-[3-(Morpholino)propyl]-1H-indazol-3-yl]acetamide **436161-16-9P**, 2-[1-(3-(tert-Butyldimethylsilyloxy)propyl)-1H-indazol-3-yl]acetamide **436161-56-7P**, 2-[1-(3-Aminopropyl)-1H-indazol-3-yl]acetamide **436161-65-8P**, 2-[1-(3-Methoxypropyl)indazol-3-yl]acetamide **436161-74-9P**, 2-[1-(3-Dimethylaminopropyl)-1H-indazol-3-yl]thioacetamide

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of indazolyl-substituted pyrroline compds. as kinase inhibitors for treating or ameliorating kinase-mediated disorders)

RN 436159-87-4 HCAPLUS

CN 1H-Indazole-3-acetamide, 1-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)



RN 436160-16-6 HCAPLUS

CN 1H-Indazole-3-acetic acid, 5-chloro-1-(oxiranylmethyl)- (9CI) (CA INDEX NAME)



RN 436160-17-7 HCAPLUS

CN 1H-Indazole-3-acetamide, 5-chloro-1-[3-(dimethylamino)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)



RN 436161-11-4 HCAPLUS
CN 1H-Indazole-3-acetamide, 1-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 436161-16-9 HCAPLUS
CN 1H-Indazole-3-acetamide, 1-[3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 436161-56-7 HCAPLUS
CN 1H-Indazole-3-acetamide, 1-(3-aminopropyl)- (9CI) (CA INDEX NAME)



```
RN   436161-65-8  HCAPLUS
CN   1H-Indazole-3-acetamide, 1-(3-methoxypropyl)- (9CI)  (CA INDEX NAME)
```



```
RN   436161-74-9  HCAPLUS
CN   1H-Indazole-3-ethanethioamide, 1-[3-(dimethylamino)propyl]- (9CI)  (CA
     INDEX NAME)
```



```
L14  ANSWER 2 OF 3  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2001:12481  HCAPLUS
DOCUMENT NUMBER:          134:71905
TITLE:                    Preparation of indazole peptidomimetics as thrombin
                          receptor antagonists
INVENTOR(S):              Zhang, Han-cheng; Maryanoff, Bruce E.; Pandey, Anjali;
                          Scarborough, Robert M.
PATENT ASSIGNEE(S):       Ortho-Mcneil Pharmaceutical, Inc., USA; Cor
                          Therapeutics, Inc.
SOURCE:                   PCT Int. Appl., 51 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
     WO 2001000656        A2    20010104    WO 2000-US17718        20000628 <--
     WO 2001000656        A3    20010525
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
             CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
             ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
             LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
             SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
```

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 2003199455 A1 20031023 US 2003-403218 20030331 <--
PRIORITY APPLN. INFO.: US 1999-141553P P 19990629
US 2000-603338 A 20000626
OTHER SOURCE(S): MARPAT 134:71905
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Indazole derivs. I [A1 and A2 are certain D- or L-amino acid residues which may be substituted; R1 = amino, alkylamino, arylamino, heteroalkyl, etc.; R2, R3 = H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroalkyl, indanyl, etc. or R2R3N = (un)substituted piperidinyl, piperazinyl, morpholino, or pyrrolidinyl; R4 = (un)substituted aryl, arylalkyl, cycloalkyl, heteroaryl; X = O, S; m = 0-3; n = 1 or 2; p = 0 or 1] were prepared as thrombin receptor antagonists for the treatment of diseases associated with thrombosis, restenosis, **hypertension**, heart failure, arrhythmia, inflammation, angina, stroke, atherosclerosis, ischemic conditions, angiogenesis related disorders, cancer, and neurodegenerative disorders. **Thus**, compound II, prepared by a multistep procedure starting from 6-nitroindole (scheme given), showed IC50 = 0.31 and 0.04 μM, resp., in the thrombin-induced gel-filtered platelet aggregation and thrombin receptor binding assays.

IT **315203-31-7P 315203-32-8P 315203-33-9P**
315203-34-0P 315203-35-1P 315203-36-2P
315203-41-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indazole peptidomimetics as thrombin receptor antagonists)

RN 315203-31-7 HCAPLUS

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[(phenylmethyl)amino]carbonyl]propyl]-α-[[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indazol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 315203-32-8 HCAPLUS
CN Benzenepropanamide, N-[(1S)-3-amino-1-[[(phenylmethyl)amino]carbonyl]propyl]-4-chloro-α-[[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indazol-6-yl]amino]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 315203-33-9 HCAPLUS
CN L-Alaninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indazol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 315203-34-0 HCAPLUS
CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(1R)-1-phenylethyl]amino]carbonyl]propyl]-α-[[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indazol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 315203-35-1 HCAPLUS
CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(1S)-2-hydroxy-1-phenylethyl]amino]carbonyl]propyl]-α-[[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indazol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 315203-36-2 HCAPLUS
CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indazol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 315203-41-9 HCAPLUS

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[(phenylmethyl)amino]carbonyl]propyl]-α-[[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indazol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, dihydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **315203-39-5P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of indazole peptidomimetics as thrombin receptor antagonists)

RN 315203-39-5 HCAPLUS

CN 1H-Indazol-6-amine, 1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



```
L14  ANSWER 3 OF 3  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2001:12414  HCAPLUS
DOCUMENT NUMBER:          134:71904
TITLE:                    Preparation of indole and indazole urea-peptoids as
                          thrombin receptor antagonists
INVENTOR(S):              McComsey, David F.; Hoekstra, William J.; Maryanoff,
                          Bruce E.; Zhang, Han-cheng
PATENT ASSIGNEE(S):       Ortho-McNeil Pharmaceutical, Inc., USA; Cor
                          Therapeutics, Inc.
SOURCE:                   PCT Int. Appl., 44 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.          KIND   DATE       APPLICATION NO.        DATE
     ---------------     ----   --------   --------------------   --------
     WO 2001000576        A1    20010104   WO 2000-US18021        20000629 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
             CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
             ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
             LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
             SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW:  GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
             CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     US 6365617           B1    20020402   US 2000-603229         20000626 <--
PRIORITY APPLN. INFO.:                     US 1999-141555P     P  19990629
                                           US 2000-603229      A  20000626
OTHER SOURCE(S):          MARPAT 134:71904
GI
```



I



II

AB Indole and indazole urea-peptoid compds. I [R1 = amino, alkylamino, arylamino, heteroalkyl, etc.; R2 = (un)substituted aryl, arylalkyl, cycloalkyl, heteroaryl; R3 = H, alkyl; R4, R5 = H, alkyl, aminoalkyl, aryl, aralkyl, heteroaryl, cycloalkyl, etc.; R6, R7 = H, alkyl, aminoalkyl, aminocycloalkyl, aryl, heteroarylalkyl, etc.; R8 = H, alkyl, aminoalkyl, allyl, cycloalkyl, aryl, heteroaryl, etc.; X = CH, N; n = 0-3; m = 0 or 1; p = 1 or 2] were prepared as thrombin receptor antagonists for the treatment of diseases associated with thrombosis, restenosis, **hypertension**, heart failure, arrhythmia, inflammation, angina, stroke, atherosclerosis, ischemic conditions, angiogenesis related disorders, cancer, and neurodegenerative disorders. **Thus**, compound II, prepared by a multistep procedure starting from 6-nitroindole (scheme given), showed IC50 = 1.3 and 0.5 M, resp., in the thrombin-induced gel-filtered platelet aggregation and thrombin receptor binding assays.

IT **314751-99-0P 314752-01-7P 314752-07-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indole and indazole urea-peptoids as thrombin receptor antagonists)

RN 314751-99-0 HCAPLUS

CN Glycinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indazol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N2-(2-aminoethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 314752-01-7 HCAPLUS
CN Glycinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indazol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N2-(4-aminobutyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 314752-07-3 HCAPLUS
CN Benzenepropanamide, N-(3-aminopropyl)-α-[[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indazol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



```
REFERENCE COUNT:           7     THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
                                 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d l13 ibib abs hitstr 1-15

L13  ANSWER 1 OF 38  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:          2003:836590  HCAPLUS
DOCUMENT NUMBER:           139:323437
TITLE:                     Preparation of heteroaryls for therapeutic use in
                           pharmaceutical compositions as kinase inhibitors for
                           treatment of hyperproliferative diseases, including
                           cancer
INVENTOR(S):               Li, Qun; Woods, Keith W.; Zhu, Gui-Dong; Fischer, John
                           P.; Gong, Jianchun; Li, Tongmei; Gandhi, Virajkumar;
                           Thomas, Sheela A.; Packard, Garrick K.; Song,
                           Xiaohong; Abrams, Jason N.; Diebold, Robert B.;
                           Dinges, Jurgen; Hutchins, Charles W.; Stoll, Vincent
                           S.; Rosenberg, Saul H.; Giranda, Vincent L.
PATENT ASSIGNEE(S):        Abbott Laboratories, USA
SOURCE:                    U.S. Pat. Appl. Publ., 120 pp., which
                           CODEN: USXXCO
DOCUMENT TYPE:             Patent
LANGUAGE:                  English
FAMILY ACC. NUM. COUNT:    1
PATENT INFORMATION:

     PATENT NO.            KIND   DATE        APPLICATION NO.        DATE
     ---------------       ----   --------    --------------------   --------
     US 2003199511          A1    20031023    US 2002-317914         20021212 <--
     US 6831175             B2    20041214
PRIORITY APPLN. INFO.:                        US 2001-341356P     P  20011213
                                              US 2001-341474P     P  20011217
OTHER SOURCE(S):           MARPAT 139:323437
GI
```


I


II

AB Compds., such as I [X = CR8, N (R8 = H, alkyl, NH2, etc.); X1, Y, Z = C, N; Y1 = CR9, N (R9 = H, L2L3(R3)(R6)); provided that 0-2 of X, X1, Y, Y1 and Z are N; L 1 = a bond, CO, S, etc.; L2 = a bond, O, S, etc.; L3 = a bond, alkylidene, alkylene; R1 = aryl, heteroaryl, heterocyclyl; R2 and R4 are absent or selected from H, alkenyl, alkyl, etc.; R2 and L1, together with the carbon atoms to which they are attached, form aryl, heteroaryl, heterocyclyl; R2 and L2, together with the carbon atoms to which they are attached, form aryl, heteroaryl, heterocyclyl; R3 = absent, H, aryl, arylalkoxy, etc.; R6 = H, aryl, arylalkoxy, etc.; R7 = absent, H, alkyl, cyanoalkenyl, etc.; R7 and L1, together with the carbon atoms to which they are attached, form aryl, heteroaryl, heterocyclyl; with the provisos], were prepared for therapeutic use as protein kinase inhibitors. **Thus**, 3,5-dibromopyridine was treated with HOCH2CH2NMe2, followed by 4-vinylpyridine to give the pyridinylethenylpyridine II. The prepared heteroaryls were assayed for inhibition of enzymic activity against kinases Akt1, Akt2, Akt3, PKA, PKC, Erk2 Chk1, Cdc2, Src, CK2, MAPKAP kinase-2 and SGK. Pharmaceutical compns. comprising aryls and heteroaryls I were claimed.

IT **552325-35-6P 552325-36-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heteroaryls for therapeutic use in pharmaceutical compns. as kinase inhibitors for treatment of hyperproliferative diseases, including cancer)

RN 552325-35-6 HCAPLUS

CN 1H-Indole-3-ethanamine, α-[[[5-(1,3-dimethyl-1H-indazol-5-yl)-3-pyridinyl]oxy]methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 552325-36-7 HCAPLUS

CN   1H-Indole-3-ethanamine, α-[[[5-(1,3-dimethyl-1H-indazol-5-yl)-3-pyridinyl]oxy]methyl]-, (αS)-, trifluoroacetate (5:14) (9CI) (CA INDEX NAME)

CM   1

CRN 552325-35-6
CMF C25 H25 N5 O

Absolute stereochemistry.



CM   2

CRN 76-05-1
CMF C2 H F3 O2



IT   **552331-30-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heteroaryls for therapeutic use in pharmaceutical compns. as kinase inhibitors for treatment of hyperproliferative diseases, including cancer)

RN   552331-30-3 HCAPLUS
CN   1H-Indazole, 5-bromo-1,3-dimethyl- (9CI) (CA INDEX NAME)



```
REFERENCE COUNT:         64     THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13  ANSWER 2 OF 38  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        2003:777399  HCAPLUS
DOCUMENT NUMBER:         139:292151
TITLE:                   Preparation of pyridine derivatives as protein kinase
                         inhibitors
INVENTOR(S):             Li, Qun; Woods, Keith W.; Zhu, Gui-Dong; Fischer, John
                         P.; Gong, Jianchun; Li, Tongmei; Gandhi, Virajkumar;
                         Thomas, Sheela A.; Packard, Garrick K.; Song,
                         Xiaohong; Abrams, Jason N.; Diebold, Robert; Dinges,
                         Jurgen; Hutchins, Charles; Stoll, Vincent S.;
                         Rosenberg, Saul H.; Giranda, Vincent L.
PATENT ASSIGNEE(S):      USA
SOURCE:                  U.S. Pat. Appl. Publ., 120 pp., Cont.-in-part of U.S.
                         Ser. No. 23,363, abandoned.
                         CODEN: USXXCO
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  2
PATENT INFORMATION:

     PATENT NO.          KIND   DATE       APPLICATION NO.        DATE
     ---------------     ----   --------   --------------------   --------
     US 2003187026        A1    20031002   US 2002-295833         20021118 <--
     CA 2470214           AA    20030626   CA 2002-2470214        20021212 <--
     WO 2003051366        A2    20030626   WO 2002-US39915        20021212 <--
     WO 2003051366        A3    20040325
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2002353147        A1    20030630   AU 2002-353147         20021212 <--
     EP 1463505           A2    20041006   EP 2002-790126         20021212
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
     JP 2005516927        T2    20050609   JP 2003-552299         20021212
PRIORITY APPLN. INFO.:                     US 2001-23363       B2 20011213
                                           US 2002-295833      A  20021118
                                           WO 2002-US39915     W  20021212
OTHER SOURCE(S):         MARPAT 139:292151
GI
```



I



II

AB The title compds. I [X = CR8, N (R8 = H, alkyl, NH2, etc.); X1, Y, Z = C, N; Y1 = CR9, N (R9 = H, L2L3(R3)(R6)); provided that 0-2 of X, X1, Y, Y1 and Z are N; L 1 = a bond, CO, S, etc.; L2 = a bond, O, S, etc.; L3 = a bond, alkylidene, alkylene; R1 = aryl, heteroaryl, heterocyclyl; R2 and R4 are absent or selected from H, alkenyl, alkyl, etc.; R2 and L1, together with the carbon atoms to which they are attached, form aryl, heteroaryl, heterocyclyl; R2 and L2, together with the carbon atoms to which they are attached, form aryl, heteroaryl, heterocyclyl; R3 = absent, H, aryl, arylalkoxy, etc.; R6 = H, aryl, arylalkoxy, etc.; R7 = absent, H, alkyl, cyanoalkenyl, etc.; R7 and L1, together with the carbon atoms to which they are attached, form aryl, heteroaryl, heterocyclyl; with the provisos] were prepared for use as kinase inhibitors with 77-100% inhibition of Akt at 1 μM. **Thus**, 3,5-dibromopyridine was treated with HOCH2CH2NMe2, followed by 4-vinylpyridine to give the pyridinylethenylpyridine (E)-II. Pharmaceutical composition comprising the compound I was claimed.

IT **552325-35-6P 552325-36-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridine derivs. as protein kinase inhibitors)

RN 552325-35-6 HCAPLUS
CN 1H-Indole-3-ethanamine, α-[[[5-(1,3-dimethyl-1H-indazol-5-yl)-3-pyridinyl]oxy]methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 552325-36-7 HCAPLUS
CN 1H-Indole-3-ethanamine, α-[[[5-(1,3-dimethyl-1H-indazol-5-yl)-3-pyridinyl]oxy]methyl]-, (αS)-, trifluoroacetate (5:14) (9CI) (CA INDEX NAME)

CM 1

CRN 552325-35-6
CMF C25 H25 N5 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2


$F-\overset{F}{\underset{F}{C}}-CO_2H$

IT **552331-30-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyridine derivs. as protein kinase inhibitors)
RN 552331-30-3 HCAPLUS
CN 1H-Indazole, 5-bromo-1,3-dimethyl- (9CI) (CA INDEX NAME)



L13 ANSWER 3 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:678772 HCAPLUS

```
DOCUMENT NUMBER:        139:214465
TITLE:                  Preparation of substituted phenylalkanoic acid
                        derivatives as inhibitors of prostaglandin and
                        leukotriene production
INVENTOR(S):            Shoda, Motoshi; Kuriyama, Hiroshi
PATENT ASSIGNEE(S):     Asahi Kasei Kabushiki Kaisha, Japan
SOURCE:                 PCT Int. Appl., 607 pp.
                        CODEN: PIXXD2
DOCUMENT TYPE:          Patent
LANGUAGE:               Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE         APPLICATION NO.         DATE
     ---------------     ----   --------     --------------------    --------
     WO 2003070686        A1    20030828     WO 2003-JP1849          20030220 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,
             LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,
             PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
             UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2477208           AA    20030828     CA 2003-2477208         20030220 <--
     AU 2003211384        A1    20030909     AU 2003-211384          20030220 <--
     US 2004044258        A1    20040304     US 2003-368435          20030220 <--
     US 6867320           B2    20050315
     EP 1477472           A1    20041117     EP 2003-706983          20030220
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRIORITY APPLN. INFO.:                       JP 2002-45293       A   20020221
                                             JP 2002-301543      A   20021016
                                             US 2002-358337P     P   20020222
                                             US 2002-419098P     P   20021018
                                             WO 2003-JP1849      W   20030220
OTHER SOURCE(S):        MARPAT 139:214465
GI
```



I

AB   Compds. represented by the general formula (I) [wherein n is an integer of 1 to 3; R represents C3-8 alkyl, a group represented by R1(CH2)k- (k is an integer of 0 to 3; and R1 represents C3-7 saturated cycloalkyl or C6-8 fused-ring saturated alkyl, provided that R1 may be substituted by C1-4 alkyl), etc.; and Ar represents a bicyclic fused-ring group, e.g., naphthalen-1-yl, indolyl, benzothiazolyl, quinolyl, isoquinolyl, indazolyl] or salts thereof are prepared The compds. I or salt thereof have prostaglandin and leukotriene production inhibitory activity and are useful for the prevention of and treatments for various acute or chronic inflammatory diseases attributable to the lipid mediator, allergic diseases, and autoimmune diseases, and for antipyresis and/or analgesia. **Thus**, 3-(3-bromo-5-fluoro-4-cyclopentyloxyphenyl)propionic acid Me ester (preparation given) was coupled with 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-methylaniline in the presence of (Ph3P)4Pd in 2 M aqueous Na2CO3 solution and toluene at 100° for 15 h to give 3-(4'-amino-6-cyclopentyloxy-5-fluoro-3'-methyl-1,1'-biphenyl-3-yl)propionic acid Me ester which was dissolved in AcOH under ice cooling, treated with aqueous NaNO2 solution, stirred for 30 min, treated with urea, warmed to room temperature, and stirred for 30 min to give 3-[4-cyclopentyloxy-3-fluoro-5-(1H-indazol-5-yl)phenyl]propionic acid Me ester (II). Saponification of II by 2 N aqueous NaOH in MeOH at 60° for 16 h followed by concentration under reduced pressure and acidification with 5% aqueous HCl under ice-cooling gave 3-[4-cyclopentyloxy-3-fluoro-5-(1H-indazol-5-yl)phenyl]propionic acid (III). III, 3-[4-(cyclohexylmethoxy)-3-(6-hydroxynaphthalen-2-yl)phenyl]propionic acid, and 3-[4-(cyclopentylmethoxy)-3-(1H-indol-5-yl)phenyl]propionic acid inhibited the interleukin-1β-stimulated prostaglandin E2 in human osteosarcoma cell (MG-63) by ≥50% at 0.4 μM.

IT **590416-83-4P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted phenylalkanoic acid derivs. as inhibitors of prostaglandin and leukotriene production for prevention or treatment of inflammations, allergies, and autoimmune diseases, and for antipyresis and/or analgesia)
RN 590416-83-4 HCAPLUS
CN Benzenepropanoic acid, 4-(cyclopentyloxy)-3-(1,3-dimethyl-1H-indazol-5-yl)-, methyl ester (9CI) (CA INDEX NAME)



IT **590416-84-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted phenylalkanoic acid derivs. as inhibitors of prostaglandin and leukotriene production for prevention or treatment of inflammations, allergies, and autoimmune diseases, and for antipyresis and/or analgesia)
RN 590416-84-5 HCAPLUS

```
CN   Benzenepropanoic acid, 4-(cyclopentyloxy)-3-(1,3-dimethyl-1H-indazol-5-yl)-
       (9CI)  (CA INDEX NAME)
```



```
REFERENCE COUNT:            5     THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
                                  RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13  ANSWER 4 OF 38  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:           2003:511082  HCAPLUS
DOCUMENT NUMBER:            139:85343
TITLE:                      Preparation of 2-(heterocyclylmethyl)benzimidazoles as
                            respiratory syncytial virus antiviral agents
INVENTOR(S):                Yu, Kuo-long; Wang, Xiangdong; Sun, Yaxiong; Cianci,
                            Christopher; Thuring, Jan Willem; Combrink, Keith;
                            Meanwell, Nicholas; Zhang, Yi; Civiello, Rita L.
PATENT ASSIGNEE(S):         Bristol-Myers Squibb Company, USA
SOURCE:                     PCT Int. Appl., 149 pp.
                            CODEN: PIXXD2
DOCUMENT TYPE:              Patent
LANGUAGE:                   English
FAMILY ACC. NUM. COUNT:     1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE       APPLICATION NO.       DATE
     ---------------     ----   --------   --------------------  --------
     WO 2003053344        A2    20030703   WO 2002-US39220       20021206 <--
     WO 2003053344        A3    20031113
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 2003207868        A1    20031106   US 2002-309505        20021204 <--
     US 6919331           B2    20050719
     EP 1461035           A2    20040929   EP 2002-797226        20021206
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
PRIORITY APPLN. INFO.:                     US 2001-339025P    P  20011210
                                           WO 2002-US39220    W  20021206
OTHER SOURCE(S):            MARPAT 139:85343
GI
```



I



II

AB Title compds. I [wherein R1 = (CRaRb)nX; R2 = H; R3 = CONRhRi, CO2Rd, or (un)substituted alkyl; R4 = NH2, CONRhRi, heteroaryl, alkenyl, CO2Rd, N=CPh2, C(NOH)NH2, C(NH)NH2, or (un)substituted alkyl; R5 = CO2Rj or (un)substituted alkyl or alkenyl; Q = (un)substituted benzimidazolyl, benzotriazolyl, imidazopyridinyl, quinolinyl, quinazolinyl, benzyloxy, etc.; X = H or (un)substituted alkyl; Ra and Rb = independently H or (halo)alkyl; Rd = alkyl; Rh and Ri = independently H or alkyl; Rj = H or alkyl; n = 1-6; and pharmaceutically acceptable salts thereof] were prepared as antiviral compds. More particularly, the invention provides 2-(heterocyclylmethyl)benzimidazole derivs. for the treatment of respiratory syncytial virus (RSV) infection. For example, 1-isopropyl-1,3-dihydrobenzimidazol-2-one was coupled with 2-chloromethyl-1-(3-methylbutyl)-1H-benzimidazole-5-carbonitrile in the presence of Cs2CO3 in DMF to give II (95%). Disclosed compds. protected HEp-2 cells from RSV-induced cytopathic effects with EC50 values between 50 μM and 0.001 μM, compared to an EC50 of 3 μM for ribavirin. I also displayed antiviral activity by reducing viral protein expression in HEp-2 cells with EC50 values between 50 μM and 0.001 μM, compared to an EC50 value of 3 μM for ribavirin. **Thus**, I and compns. comprising I are useful for the treatment of RSV infections.

IT **554458-36-5P 554458-37-6P 554458-39-8P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(antiviral agent; preparation of (heterocyclylmethyl)benzimidazoles as RSV antiviral agents)

RN 554458-36-5 HCAPLUS

CN Propanoic acid, 2,2-dimethyl-, 4-[5-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-2-[(3-ethenyl-1H-indazol-1-yl)methyl]-1H-benzimidazol-1-yl]butyl ester (9CI) (CA INDEX NAME)



RN 554458-37-6 HCAPLUS
CN Carbamic acid, [[2-[(3-ethenyl-1H-indazol-1-yl)methyl]-1-(4-hydroxybutyl)-1H-benzimidazol-5-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 554458-39-8 HCAPLUS
CN Carbamic acid, [[2-[(3-ethyl-1H-indazol-1-yl)methyl]-1-(4-hydroxybutyl)-1H-benzimidazol-5-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **554458-38-7P 554458-40-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antiviral agent; preparation of (heterocyclylmethyl)benzimidazoles as RSV antiviral agents)
RN 554458-38-7 HCAPLUS
CN 1H-Benzimidazole-1-butanol, 5-(aminomethyl)-2-[(3-ethenyl-1H-indazol-1-yl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 554458-40-1 HCAPLUS
CN 1H-Benzimidazole-1-butanol, 5-(aminomethyl)-2-[(3-ethyl-1H-indazol-1-yl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

```
L13  ANSWER 5 OF 38  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2003:491046  HCAPLUS
DOCUMENT NUMBER:          139:69152
TITLE:                    Preparation of pyridine derivatives as protein kinase
                          inhibitors
INVENTOR(S):              Li, Qun; Woods, Keith W.; Zhu, Gui-Dong; Fischer, John
                          P.; Gong, Jianchun; Li, Tongmei; Gandhi, Viraj;
                          Thomas, Sheela A.; Packard, Garrick; Song, Xiaohong;
                          Abrams, Jason N.; Diebold, Robert; Dinges, Jurgen;
                          Hutchins, Charles; Stoll, Vincent S.; Rosenberg, Saul
                          H.; Giranda, Vincent L.
PATENT ASSIGNEE(S):       Abbott Laboratories, USA
SOURCE:                   PCT Int. Appl., 261 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.          KIND    DATE         APPLICATION NO.         DATE
     ---------------     ----    --------     --------------------    --------
     WO 2003051366        A2     20030626     WO 2002-US39915         20021212 <--
     WO 2003051366        A3     20040325
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 2003187026          A1     20031002   US 2002-295833         20021118 <--
     CA 2470214             AA     20030626   CA 2002-2470214        20021212 <--
     AU 2002353147          A1     20030630   AU 2002-353147         20021212 <--
     EP 1463505             A2     20041006   EP 2002-790126         20021212
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
     JP 2005516927          T2     20050609   JP 2003-552299         20021212
PRIORITY APPLN. INFO.:                        US 2001-23363       A  20011213
                                              US 2002-295833      A  20021118
                                              WO 2002-US39915     W  20021212
OTHER SOURCE(S):            MARPAT 139:69152
GI
```



I



II

```
AB    Pyridines I [X, X1, Y, Y1, Z = N, (un)substituted CH; L = O, alkenyl,
      alkynyl, CO, S, s(O), SO2, (un)substituted NH, SO2NH, NHSO2, CH2, CH2NH,
      NHCO, CONH; R = aryl, heteroaryl, heterocyclic] were prepared for use as
      kinase inhibitors with 77-100% inhibition of Akt at 1 μM.   Thus
      , 3,5-dibromopyridine was treated with HOCH2CH2NMe2, followed by
      4-vinylpyridine to give the pyridinylethenylpyridine (E)-II.
IT    552331-30-3P
      RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
      (Reactant or reagent)
         (preparation of pyridine derivs. as protein kinase inhibitors)
RN    552331-30-3  HCAPLUS
CN    1H-Indazole, 5-bromo-1,3-dimethyl- (9CI)  (CA INDEX NAME)
```



```
IT    552325-35-6P 552325-36-7P
      RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
      study); PREP (Preparation); USES (Uses)
         (preparation of pyridine derivs. as protein kinase inhibitors)
RN    552325-35-6  HCAPLUS
CN    1H-Indole-3-ethanamine, α-[[[5-(1,3-dimethyl-1H-indazol-5-yl)-3-
```

pyridinyl]oxy]methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN   552325-36-7 HCAPLUS

CN   1H-Indole-3-ethanamine, α-[[[5-(1,3-dimethyl-1H-indazol-5-yl)-3-pyridinyl]oxy]methyl]-, (αS)-, trifluoroacetate (5:14) (9CI) (CA INDEX NAME)

CM   1

CRN 552325-35-6
CMF C25 H25 N5 O

Absolute stereochemistry.



CM   2

CRN 76-05-1
CMF C2 H F3 O2



$\mathrm{F}-\overset{\mathrm{F}}{\underset{\mathrm{F}}{\mathrm{C}}}-\mathrm{CO_2H}$

```
L13  ANSWER 6 OF 38  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2002:676018  HCAPLUS
DOCUMENT NUMBER:          137:216824
TITLE:                    Preparation of xanthine derivatives as
                          dipeptidylpeptidase-IV inhibitors
INVENTOR(S):              Himmelsbach, Frank; Mark, Michael; Eckhardt, Matthias;
                          Langkopf, Elke; Maier, Roland; Lotz, Ralf
PATENT ASSIGNEE(S):       Boehringer Ingelheim Pharma K.-G., Germany
SOURCE:                   PCT Int. Appl., 373 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 German
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.          KIND   DATE       APPLICATION NO.        DATE
     ---------------     ----   --------   --------------------   --------
     WO 2002068420        A1    20020906   WO 2002-EP1820         20020221 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
             US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     DE 10109021          A1    20020905   DE 2001-10109021       20010224 <--
     DE 10117803          A1    20021024   DE 2001-10117803       20010410 <--
     DE 10140345          A1    20030227   DE 2001-10140345       20010817 <--
     DE 10203486          A1    20030731   DE 2002-10203486       20020130 <--
     CA 2435730           AA    20020906   CA 2002-2435730        20020221 <--
     EP 1368349           A1    20031210   EP 2002-701288         20020221 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     EE 200300409         A     20031215   EE 2003-409            20020221 <--
     BR 2002007767        A     20040330   BR 2002-7767           20020221
     JP 2004522786        T2    20040729   JP 2002-567932         20020221
     BG 108093            A     20040831   BG 2003-108093         20030813
     NO 2003003726        A     20030821   NO 2003-3726           20030821 <--
     US 2004077645        A1    20040422   US 2003-467961         20031205 <--
PRIORITY APPLN. INFO.:                     DE 2001-10109021    A  20010224
                                           DE 2001-10117803    A  20010410
                                           DE 2001-10140345    A  20010817
                                           DE 2002-10203486    A  20020130
                                           WO 2002-EP1820      W  20020221
OTHER SOURCE(S):         MARPAT 137:216824
GI
```



I



II

AB Xanthine derivs. of formula I [R1, R2 = H, alkyl, alkenyl, etc.; R3 = alkyl, arylalkyl, etc.; R4 = heterocyclyl, cycloalkyl, aminoalkyl, etc.] are prepared which exhibit an inhibitory effect on the activity of the dipeptidylpeptidase-IV enzyme. Pharmaceutical compns. containing I are described. **Thus**, II was prepared and had an IC50 of 22 nM against dipeptidylpeptidase-IV.

IT **454708-53-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of xanthine derivs. as dipeptidylpeptidase-IV inhibitors)

RN 454708-53-3 HCAPLUS

CN 1H-Purine-2,6-dione, 8-(3-amino-1-piperidinyl)-3,7-dihydro-3-methyl-7-(3-methyl-2-butenyl)-1-[(1-methyl-1H-indazol-3-yl)methyl]- (9CI) (CA INDEX NAME)



IT **454709-71-8P 454711-77-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of xanthine derivs. as dipeptidylpeptidase-IV inhibitors)

RN 454709-71-8 HCAPLUS

CN Carbamic acid, [1-[2,3,6,7-tetrahydro-3-methyl-7-(3-methyl-2-butenyl)-1-[(1-methyl-1H-indazol-3-yl)methyl]-2,6-dioxo-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



```
RN   454711-77-4  HCAPLUS
CN   1H-Purine-2,6-dione, 8-chloro-3,7-dihydro-3-methyl-7-(3-methyl-2-butenyl)-
     1-[(1-methyl-1H-indazol-3-yl)methyl]- (9CI)  (CA INDEX NAME)
```



```
REFERENCE COUNT:          2       THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
                                  RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13  ANSWER 7 OF 38  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2002:575068  HCAPLUS
DOCUMENT NUMBER:          137:140534
TITLE:                    Preparation of pyrimidinamines as angiogenesis
                          modulators
INVENTOR(S):              Boloor, Amogh; Cheung, Mui; Davis, Ronda; Harris,
                          Philip Anthony; Hinkle, Kevin; Mook, Robert Anthony;
                          Stafford, Jeffery Alan; Veal, James Martin
PATENT ASSIGNEE(S):       Glaxo Group Limited, UK
SOURCE:                   PCT Int. Appl., 133 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
     WO 2002059110        A1    20020801    WO 2001-US49367        20011219 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
             UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW:  GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2432000           AA     20020801    CA 2001-2432000         20011219 <--
     EP 1343782           A1     20030917    EP 2001-994315          20011219 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     BR 2001016452        A      20030930    BR 2001-16452           20011219 <--
     JP 2004517925        T2     20040617    JP 2002-559412          20011219
     CN 1549813           A      20041124    CN 2001-822750          20011219
     NZ 526542            A      20050128    NZ 2001-526542          20011219
     NO 2003002831        A      20030815    NO 2003-2831            20030620 <--
     US 2004242578        A1     20041202    US 2004-451305          20040609 <--
PRIORITY APPLN. INFO.:                       US 2000-257526P      P  20001221
                                             US 2001-262403P      P  20010116
                                             WO 2001-US49367      W  20011219
OTHER SOURCE(S):          MARPAT 137:140534
GI
```



I

```
AB   The title compds. [I; D = (un)substituted indazol-6-yl,
     benzimidazolyl-5-yl; X4 = H, alkyl, haloalkyl, etc.; W = N, CR; R = H,
     halo, CN; Q1 = H, halo, haloalkyl, etc.; Q2 = A1, A2; Q3 = A1 when Q2 = A2
     and Q3 = A2 when Q2 = A1; A1 = H, halo, alkyl, haloalkyl, alkoxy; A2 =
     ZmZ1Z2; Z = CH2 and m = 0-3; Z = NR2 and m = 0-1; Z = O and m = 0-1; Z =
     CH2NR2 and m = 0-1; Z1 = SO2, SO, CO; Z2 = alkyl, NR3R4, aryl, etc.; R2-R4
     = H, alkyl, cycloalkyl, etc.; with provisos], useful as VEGFR2 inhibitors
     in the treatment of hyperproliferative diseases, were prepared  Thus
     , reacting tert-Bu 6-[(2-chloro-5-fluoro-4-pyrimidinyl)(methyl)amino]-3-
     methyl-1H-indazole-1-carboxylate (preparation given) with 3-amino-4-
     methoxyphenyl Et sulfone in the presence of drop of concentrate HCl in iso-PrOH
     followed by deprotection afforded 42% I [D = 3-methyl-1H-indazol-6-yl; X4
     = Me; W = CF; Q1 = OMe; Q2 = H; Q3 = SO2Et] which showed IC50 of 201-500
     nM in HUVEC proliferation assay.
IT   444731-21-9P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
        (preparation of pyrimidinamines as angiogenesis modulators)
RN   444731-21-9  HCAPLUS
CN   2,4-Pyrimidinediamine, N4-(1,3-dimethyl-1H-indazol-6-yl)-N4-methyl-N2-[3-
     [(methylsulfonyl)methyl]phenyl]- (9CI)  (CA INDEX NAME)
```



```
REFERENCE COUNT:          6     THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13  ANSWER 8 OF 38  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2002:449674  HCAPLUS
DOCUMENT NUMBER:          137:33321
TITLE:                    Preparation of indazolyl-substituted pyrroline
                          compounds as kinase inhibitors for treating or
                          ameliorating kinase-mediated disorders
INVENTOR(S):              Zhang, Han-Cheng; Maryanoff, Bruce; Conway, Bruce;
                          White, Kimberly; Ye, Hong; Hecker, Leonard R.;
                          McComsey, David F.
PATENT ASSIGNEE(S):       Ortho-McNeil Pharmaceutical, Inc., USA
SOURCE:                   PCT Int. Appl., 148 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     ---------------     ----   --------    --------------------     --------
     WO 2002046183        A2    20020613    WO 2001-US47689          20011206 <--
     WO 2002046183        A3    20020906
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
             UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW:  GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2431166           AA    20020613    CA 2001-2431166          20011206 <--
     AU 2002030727        A5    20020618    AU 2002-30727            20011206 <--
     US 2003055097        A1    20030320    US 2001-13181            20011206 <--
     US 6849643           B2    20050201
     EP 1362047           A2    20031119    EP 2001-990971           20011206 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     JP 2004515499        T2    20040527    JP 2002-547921           20011206
     BR 2001016468        A     20040629    BR 2001-16468            20011206
     NZ 526356            A     20050225    NZ 2001-526356           20011206
     NO 2003002625        A     20030805    NO 2003-2625             20030610 <--
     ZA 2003005239        A     20041007    ZA 2003-5239             20030707
     US 2004259928        A1    20041223    US 2004-885373           20040706 <--
     US 2005004202        A1    20050106    US 2004-909537           20040802 <--
PRIORITY APPLN. INFO.:                      US 2000-254166P      P   20001208
```

US 2001-13181 A3 20011206
WO 2001-US47689 W 20011206

OTHER SOURCE(S): MARPAT 137:33321

GI



I

AB Novel indazolyl-substituted pyrroline compds. of formula [I; R1, R2 = H, C1-5 alkyl, C2-8 alkenyl, or C2-8 alkynyl (wherein alkyl, alkenyl and alkynyl are optionally substituted), -C(O)-C1-8 alkyl, -C(O)-aryl-C(O)-O-C1-8 alkyl, -C(O)-O-aryl, -C(O)-NH-C1-8 alkyl, -C(O)-NH-aryl-C(O)-N-[C1-8 alkyl]2, -SO2-C1-8 alkyl, -SO2-aryl, aryl, heteroaryl (wherein aryl and heteroaryl are optionally substituted); X = N, CR5; R3, R4 = H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 alkoxy, C(O)H-C(O)-C1-8 alkyl, CO2H, C(O)-O-C1-8 alkyl, CONH2, C(:NH)NH2, C(O)-NH-C1-8 alkyl, C(O)-N(C1-8 alkyl)2, SH, S-C1-8 alkyl, SO2-C1-8 alkyl, SO2NH2, SO2-NH-C1-8 alkyl, SO2-N(C1-8 alkyl)2, N-(un)substituted amino or amino-C1-8 alkyl cyano, halo, (halo)1-3-C1-8 alkyl, (halo)1-3-C1-8 alkoxy, hydroxy, hydroxy-C1-8 alkyl, nitro, aryl, -C1-8 alkylaryl, heteroaryl -C1-8 alkylheteroaryl; Y, Z = O, S, (H,OH), (H,H); with the proviso that one of Y and Z is O and the other is selected from the group consisting of O, S, (H,OH) and (H,H); R5 = hydrogen, halogen, (un)substituted C1-8 alkyl, C2-8 alkenyl, or C2-8 alkynyl] and pharmaceutically acceptable salts thereof are prepared These compds. are selective inhibitors of kinase or dual inhibitors of at least two kinases selected from protein kinase C, glycogen synthetase kinase-3, protein kinase C α, protein kinase C β-II, protein kinase C γ, glycogen synthetase kinase-3β, for treating or ameliorating kinase, and dual-kinase mediated disorders. They are useful for treating or ameliorating a kinase-mediated disorders selected from cardiovascular diseases, diabetes, diabetes-associated disorders, inflammatory diseases, immunol. disorders, dermatol. disorders, oncol. disorders and CNS disorders. **Thus**, 2-[1-(3-pyridyl)indol-3-yl]-2-oxoacetic acid Me ester (700 mg, 2.5 mmol) and 2-[1-(3-dimethylaminopropyl)-1H-indazol-3-yl]acetamide (546 mg, 2.1 mmol) were combined in dry THF (10 mL) under argon and cooled with an ice bath as 1 M potassium t-butoxide in THF (8.4 mL, 8.4 mmol) was added with stirring over a 20 min period. After 1 h, the reaction was quenched in an ice bath by adding 12 N HCl (3.5 mL, 42 mmol) slowly over a 3 min period to give, after purification by flash column chromatog., 3-[1-[3-(dimethylamino)propyl]-1H-indazol-3-yl]-4-[1-(3-pyridinyl)-1H-indol-3-yl]-1H-pyrrole-2,5-dione (II). II showed IC50 of 0.007, 0.124, and 0.213 μM against protein kinase C isoforms β-II, α, and γ, resp.

IT **436159-87-4P**, 2-[1-(3-Dimethylaminopropyl)-1H-indazol-3-yl]acetamide **436160-16-6P**, 2-(1-Glycidyl-5-chloro-1H-indazol-3-yl)acetic acid **436160-17-7P**, 2-[1-[2-Hydroxy-3-(dimethylamino)propyl]-5-chloro-1H-indazol-3-yl]acetamide

436161-11-4P, 2-[1-[3-(Morpholino)propyl]-1H-indazol-3-yl]acetamide **436161-16-9P**, 2-[1-(3-(tert-Butyldimethylsilyloxy)propyl)-1H-indazol-3-yl]acetamide
436161-56-7P, 2-[1-(3-Aminopropyl)-1H-indazol-3-yl]acetamide
436161-65-8P, 2-[1-(3-Methoxypropyl)indazol-3-yl]acetamide
436161-74-9P, 2-[1-(3-Dimethylaminopropyl)-1H-indazol-3-yl]thioacetamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of indazolyl-substituted pyrroline compds. as kinase inhibitors for treating or ameliorating kinase-mediated disorders)

RN 436159-87-4 HCAPLUS
CN 1H-Indazole-3-acetamide, 1-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)



RN 436160-16-6 HCAPLUS
CN 1H-Indazole-3-acetic acid, 5-chloro-1-(oxiranylmethyl)- (9CI) (CA INDEX NAME)



RN 436160-17-7 HCAPLUS
CN 1H-Indazole-3-acetamide, 5-chloro-1-[3-(dimethylamino)-2-hydroxypropyl]- (9CI) (CA INDEX NAME)



RN 436161-11-4 HCAPLUS
CN 1H-Indazole-3-acetamide, 1-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX

NAME)



RN 436161-16-9 HCAPLUS
CN 1H-Indazole-3-acetamide, 1-[3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 436161-56-7 HCAPLUS
CN 1H-Indazole-3-acetamide, 1-(3-aminopropyl)- (9CI) (CA INDEX NAME)



RN 436161-65-8 HCAPLUS
CN 1H-Indazole-3-acetamide, 1-(3-methoxypropyl)- (9CI) (CA INDEX NAME)



RN 436161-74-9 HCAPLUS

CN 1H-Indazole-3-ethanethioamide, 1-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)



L13 ANSWER 9 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:240762 HCAPLUS

DOCUMENT NUMBER: 136:279337

TITLE: Preparation of heterocyclylindoles with antimycotic and anti-Leishmaniasis activity

INVENTOR(S): Le Borgne, Marc; Na, Young Min; Pagniez, Fabrice; Le Baut, Guillaume; Le Pape, Patrice; Abdala, Hiam

PATENT ASSIGNEE(S): Yang Ji Chemical Company Ltd., S. Korea

SOURCE: PCT Int. Appl., 157 pp.
CODEN: PIXXD2

DOCUMENT TYPE: **Patent**

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

```
     PATENT NO.          KIND    DATE          APPLICATION NO.          DATE
     ---------------     ----    --------      --------------------     --------
     WO 2002024685        A1     20020328      WO 2001-FR2950           20010921 <--
     WO 2002024685        C1     20020926
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
             PT, RO, RU
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     FR 2814073           A1     20020322      FR 2000-12050            20000921 <--
     FR 2814073           B1     20050624
     CA 2423151           AA     20020328      CA 2001-2423151          20010921 <--
     AU 2001091973        A5     20020402    AU 2001-91973           20010921 <--
     EP 1322638           A1     20030702    EP 2001-972184          20010921 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     JP 2004509886        T2     20040402    JP 2002-529095          20010921
     KR 2003046472        A      20030612    KR 2003-704417          20030321 <--
     US 2004067998        A1     20040408    US 2003-381293          20030725 <--
PRIORITY APPLN. INFO.:                       FR 2000-12050        A  20000921
                                             WO 2001-FR2950       W  20010921
OTHER SOURCE(S):          MARPAT 136:279337
```

GI



I

AB Novel indole derivs. were prepared for use as antimycotic and antiparasitic compds. **Thus**, the indole I was prepared from the indole-3-carboxaldehyde by reduction to the 3-indolemethanol and reaction with carbonyldiimidazole. I had no fungicidal activity, but it has IC50 3±0.5 μg/mL for inhibition of Leishmania mexicana.

IT **405274-85-3P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclylindoles with antimycotic and anti-Leishmaniasis activity)

RN 405274-85-3 HCAPLUS

CN 1H-Indazole, 3-(1H-imidazol-1-ylmethyl)-1-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 10 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:122945 HCAPLUS
DOCUMENT NUMBER: 136:183540
TITLE: Preparation of aromatic amides as melanocortin receptor agonists and antagonists
INVENTOR(S): Lundstedt, Torbjoern; Skottner, Anna; Boman, Arne; Andersson, Per; Andrianov, Victor; Kalvins, Ivars

```
PATENT ASSIGNEE(S):       Melacure Therapeutics AB, Swed.; Pett, Christopher
                          Phineas
SOURCE:                   PCT Int. Appl., 38 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE       APPLICATION NO.        DATE
     ---------------     ----   --------   --------------------   --------
     WO 2002012178        A1    20020214   WO 2001-GB3556         20010807 <--
         W:  AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES,
             FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,
             KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
             MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ,
             TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG,
             KZ, MD, RU, TJ
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2417904           AA    20020214   CA 2001-2417904        20010807 <--
     AU 2001076539        A5    20020218   AU 2001-76539          20010807 <--
     EP 1309544           A1    20030514   EP 2001-954195         20010807 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     BR 2001013064        A     20030708   BR 2001-13064          20010807 <--
     JP 2004505947        T2    20040226   JP 2002-518156         20010807
     ZA 2003000883        A     20040219   ZA 2003-883            20030131
     US 2004019094        A1    20040129   US 2003-343326         20030721 <--
PRIORITY APPLN. INFO.:                     GB 2000-19359       A  20000807
                                           WO 2001-GB3556      W  20010807
OTHER SOURCE(S):          MARPAT 136:183540
GI
```



I

```
AB   The preparation of guanidine compds. [I; wherein X, Y, independently = O, N, S
     and (CH2)n, where n is 0, 1, 2, 3, 4 or 5, or a combination of these and
     may contain carbon-carbon multiple bonds and branched chains as well as
     alicyclic and heterocyclic groups; Q = H or OH; R1, R2, independently = H,
     aryl, heteroaryl] is described.  Thus, 2-chloro-3,4-
     dimethoxybenzaldehyde and N-hydroxy-N'-phenylaminoguanidine tosylate are
     reacted to give 77% N-(2-chloro-3,4-dimethoxybenzylideneamino)-N'-hydroxy-
     N''-phenylguanidine.  The prepared compds. are useful as melanocortin
     receptors and/or for treatment of disorders involving the melanocortin
     system.  Biol. data are given.
IT   398459-70-6P 398459-74-0P 398459-75-1P
```

398459-80-8P 398459-84-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aromatic amides as melanocortin receptor agonists and antagonists)

RN 398459-70-6 HCAPLUS
CN Hydrazinecarboximidamide, 2-(1H-indol-3-ylmethylene)-N-[(1-methyl-1H-indazol-3-yl)methyl]- (9CI) (CA INDEX NAME)



RN 398459-74-0 HCAPLUS
CN Hydrazinecarboximidamide, 2-[2-(5-methoxy-2-methyl-1H-indol-3-yl)ethylidene]-N-[(1-methyl-1H-indazol-3-yl)methyl]- (9CI) (CA INDEX NAME)



RN 398459-75-1 HCAPLUS
CN Hydrazinecarboximidamide, 2-[4-(1H-indol-3-yl)butylidene]-N-[(1-methyl-1H-indazol-3-yl)methyl]- (9CI) (CA INDEX NAME)



RN 398459-80-8 HCAPLUS
CN Hydrazinecarboximidamide, N-(1H-indol-3-ylmethyl)-2-[(1-methyl-1H-indazol-3-yl)methylene]- (9CI) (CA INDEX NAME)



RN 398459-84-2 HCAPLUS
CN Hydrazinecarboximidamide, N-[4-(1H-indol-3-yl)butyl]-2-[(1-methyl-1H-indazol-3-yl)methylene]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 11 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	2001:713320 HCAPLUS
DOCUMENT NUMBER:	135:257241
TITLE:	Preparation of 1-(2-aminoethyl)-6-hydroxyindazoles for treating glaucoma.
INVENTOR(S):	May, Jesse A.; Dantanarayana, Anura P.; Feng, Zixia
PATENT ASSIGNEE(S):	Alcon Universal Ltd., Switz.
SOURCE:	PCT Int. Appl., 28 pp. CODEN: PIXXD2
DOCUMENT TYPE:	**Patent**
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

```
     PATENT NO.          KIND   DATE       APPLICATION NO.        DATE
     ---------------     ----   --------   --------------------   --------
     WO 2001070702        A1    20010927   WO 2000-US31247        20001114 <--
         W:  AU, BR, CA, CN, JP, KR, MX, PL, US, ZA
         RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE, TR
     CA 2402403           AA    20010927   CA 2000-2402403        20001114 <--
     EP 1268438           A1    20030102   EP 2000-978628         20001114 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI, CY, TR
     JP 2003528085        T2    20030924   JP 2001-568912         20001114 <--
     TW 221839            B1    20041011   TW 2000-89125127       20001127
     ZA 2002006851        A     20031021   ZA 2002-6851           20020827 <--
     US 6956036           B1    20051018   US 2003-221400         20030310 <--
PRIORITY APPLN. INFO.:                     US 2000-190380P     P  20000317
                                           WO 2000-US31247     W  20001114
```

OTHER SOURCE(S): MARPAT 135:257241

GI



I

AB Title compds. [I; R1-R4 = H, halo, alkyl, CF3, alkylthio, alkylsulfonyl, cyano, etc.; R5 = halo, CF3, cyano, amino; R6-R9 = H, alkyl; R6R7C = atoms to form a cyclopropyl ring; R7R8 = (CH2)m; m = 3, 4], were prepared **Thus**, 1-(4-benzyloxy-2-fluorophenyl)ethanone (preparation given) was refluxed with N2H4 in EtOH to give 69% 6-benzyloxy-3-methyl-1H-indazole. This was converted to 1-(2-aminopropyl)-3-methyl-1H-indazol-6-ol fumarate (II) in several steps. II showed 5-HT2 receptor binding activity with IC50 = 3.0 nM. Drug formulations containing II were given.

IT **259750-27-1P 362512-11-6P 362512-13-8P**
362512-14-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminoalkylhydroxyindazoles for treating glaucoma)

RN 259750-27-1 HCAPLUS

CN 1H-Indazole-1-ethanamine, 6-methoxy-α,3-dimethyl- (9CI) (CA INDEX NAME)



RN 362512-11-6 HCAPLUS

CN 1H-Indazole-1-ethanamine, 6-methoxy-α,3-dimethyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 259750-27-1
CMF C12 H17 N3 O



CM   2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN   362512-13-8   HCAPLUS
CN   1H-Indazol-6-ol, 1-(2-aminopropyl)-3-methyl- (9CI) (CA INDEX NAME)



RN   362512-14-9   HCAPLUS
CN   1H-Indazol-6-ol, 1-(2-aminopropyl)-3-methyl-, (2E)-2-butenedioate (1:1)
(salt) (9CI) (CA INDEX NAME)

CM   1

CRN 362512-13-8
CMF C11 H15 N3 O



CM   2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



IT **362512-23-0P 362512-24-1P 362512-25-2P**
362512-27-4P 362512-28-5P 362512-29-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aminoalkylhydroxyindazoles for treating glaucoma)

RN 362512-23-0 HCAPLUS
CN 2-Propanone, 1-(6-methoxy-3-methyl-1H-indazol-1-yl)- (9CI) (CA INDEX NAME)



RN 362512-24-1 HCAPLUS
CN 1H-Indazole-1-ethanol, 6-methoxy-α,3-dimethyl- (9CI) (CA INDEX NAME)



RN 362512-25-2 HCAPLUS
CN 1H-Indazole, 1-(2-azidopropyl)-6-methoxy-3-methyl- (9CI) (CA INDEX NAME)



RN 362512-27-4 HCAPLUS
CN 2-Propanone, 1-[3-methyl-6-(phenylmethoxy)-1H-indazol-1-yl]- (9CI) (CA INDEX NAME)



RN 362512-28-5 HCAPLUS
CN 1H-Indazole-1-ethanol, α,3-dimethyl-6-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 362512-29-6 HCAPLUS
CN 1H-Indazole, 1-(2-azidopropyl)-3-methyl-6-(phenylmethoxy)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 12 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	2001:283945 HCAPLUS
DOCUMENT NUMBER:	134:311106
TITLE:	Preparation of N-heteroarylmethyl acrylamides as Fab I inhibitors
INVENTOR(S):	Miller, William H.; Newlander, Kenneth A.; Seefeld, Mark A.; Uzinskas, Irene N.; Dewolf, Walter E., Jr.; Jakas, Dalia R.
PATENT ASSIGNEE(S):	Smithkline Beecham Corporation, UK
SOURCE:	PCT Int. Appl., 119 pp. CODEN: PIXXD2
DOCUMENT TYPE:	**Patent**
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

```
     WO 2001027103          A1     20010419    WO 2000-US27844          20001006 <--
         W:  AE, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CZ, DZ, EE, GE, GH, GM,
             HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG,
             MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, TZ, UA,
             US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
             CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     CA 2387016             AA     20010419    CA 2000-2387016          20001006 <--
     EP 1226138             A1     20020731    EP 2000-968895           20001006 <--
     EP 1226138             B1     20041229
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL
     BR 2000014470          A      20020924    BR 2000-14470            20001006 <--
     JP 2003511448          T2     20030325    JP 2001-530321           20001006 <--
     NZ 517706              A      20040130    NZ 2000-517706           20001006
     AU 773218              B2     20040520    AU 2000-78747            20001006
     AT 285821              E      20050115    AT 2000-968895           20001006
     ES 2231275             T3     20050516    ES 2000-968895           20001006
     TW 534909              B      20030601    TW 2000-89120828         20001128 <--
     US 6846819             B1     20050125    US 2002-89755            20020403 <--
     ZA 2002002631          A      20030320    ZA 2002-2631             20020404 <--
     NO 2002001638          A      20020605    NO 2002-1638             20020405 <--
     US 2005250810          A1     20051110    US 2004-7927             20041209 <--
PRIORITY APPLN. INFO.:                         US 1999-158704P      P   19991008
                                               WO 2000-US27844      W   20001006
                                               US 2002-89755        A1  20020403
OTHER SOURCE(S):            MARPAT 134:311106
GI
```



I



II

AB The title compds. [I; R = (un)substituted 2-indolyl, 3-quinolinyl, 1-naphthyl, etc.; R2 = H, alkyl, cycloalkyl; R3 = (un)substituted 3-pyridyl, Ph, 3-pyrimidinyl, etc.; R4 = H, alkyl; R5 = CH2 or H, alkyl (depending on double or single bond attached)] which are Fab I inhibitors and are useful in the treatment of bacterial infections, were prepared **Thus**, amidation (E)-3-(6-aminopyridin-3-yl)acrylic acid with 1-methyl-2-(methylaminomethyl)-1H-indole (prepns. were given) in the presence of EDC, HOBt and Et3N in DMF afforded 83% (E)-II. The compds. I showed 0.05-100 μM in E. coli FabI enzyme inhibition assay.

IT **335027-62-8P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

```
     BIOL (Biological study); PREP (Preparation); USES (Uses)
        (preparation of N-heteroarylmethyl acrylamides as Fab I inhibitors)
RN   335027-62-8  HCAPLUS
CN   2-Propenamide, 3-(6-amino-3-pyridinyl)-N-methyl-N-[(1-methyl-1H-indazol-3-
     yl)methyl]-, (2E)- (9CI)  (CA INDEX NAME)

Double bond geometry as shown.
```



```
IT   124491-38-9P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (preparation of N-heteroarylmethyl acrylamides as Fab I inhibitors)
RN   124491-38-9  HCAPLUS
CN   1H-Indazole-3-methanamine, N,1-dimethyl- (9CI)  (CA INDEX NAME)
```



```
REFERENCE COUNT:          3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13  ANSWER 13 OF 38  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2001:283785  HCAPLUS
DOCUMENT NUMBER:          134:311205
TITLE:                    Preparation of N-[indolyl(or indazolyl)methyl]
                          benzamides as Fab I inhibitors
INVENTOR(S):              Miller, William H.; Newlander, Kenneth A.; Seefeld,
                          Mark A.; Uzinskas, Irene N.
PATENT ASSIGNEE(S):       Smithkline Beecham Corporation, USA
SOURCE:                   PCT Int. Appl., 44 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND    DATE        APPLICATION NO.         DATE
     ---------------     ----    --------    --------------------    --------
     WO 2001026652        A1     20010419    WO 2000-US27619         20001006 <--
         W:  AE, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CZ, DZ, EE, GE, GH, GM,
             HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG,
             MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, TZ, UA,
             US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
             CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     EP 1225894          A1    20020731    EP 2000-968801         20001006 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL
     JP 2003511414       T2    20030325    JP 2001-529442         20001006 <--
     US 6730684          B1    20040504    US 2002-89740          20020403 <--
PRIORITY APPLN. INFO.:                     US 1999-158707P     P  19991008
                                           WO 2000-US27619     W  20001006
OTHER SOURCE(S):         MARPAT 134:311205
```

GI



I



II



III

AB   The title compds. [I or II; R1 = H, alkyl; R2 = alkyl; R3 = (un)substituted Ph; 5-6 membered heteroaryl; X = H, alkyl, CN, etc.] which are Fab I inhibitors and are useful in the treatment of bacterial infections, were prepared and formulated. **Thus**, reacting 2-biphenylcarboxylic acid with 1-methyl-2-(methylaminomethyl)indole (preparation given) in the presence of EDC and HOBt in DMF afforded 25% the benzamide III. The compds. I showed IC50 of 2.0-20.0 μM in E. coli FabI enzyme inhibition assay.

IT   **335059-03-5P 335059-04-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-[indolyl(or indazolyl)methyl] benzamides as Fab I inhibitors)

RN   335059-03-5 HCAPLUS

CN   [1,1'-Biphenyl]-2-carboxamide, N-methyl-N-[(1-methyl-1H-indazol-3-yl)methyl]- (9CI) (CA INDEX NAME)



RN 335059-04-6 HCAPLUS
CN Benzamide, N-methyl-N-[(1-methyl-1H-indazol-3-yl)methyl]-2-phenoxy- (9CI) (CA INDEX NAME)



IT **124491-38-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-[indolyl(or indazolyl)methyl] benzamides as Fab I inhibitors)
RN 124491-38-9 HCAPLUS
CN 1H-Indazole-3-methanamine, N,1-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 14 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:12481 HCAPLUS
DOCUMENT NUMBER: 134:71905
TITLE: Preparation of indazole peptidomimetics as thrombin receptor antagonists
INVENTOR(S): Zhang, Han-cheng; Maryanoff, Bruce E.; Pandey, Anjali; Scarborough, Robert M.
PATENT ASSIGNEE(S): Ortho-Mcneil Pharmaceutical, Inc., USA; Cor Therapeutics, Inc.
SOURCE: PCT Int. Appl., 51 pp.

```
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.           KIND  DATE        APPLICATION NO.          DATE
     ---------------      ----  --------    --------------------     --------
     WO 2001000656         A2   20010104    WO 2000-US17718          20000628 <--
     WO 2001000656         A3   20010525
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
             CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
             ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
             LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
             SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW:  GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
             CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     US 2003199455         A1   20031023    US 2003-403218           20030331 <--
PRIORITY APPLN. INFO.:                      US 1999-141553P      P   19990629
                                            US 2000-603338       A   20000626
OTHER SOURCE(S):          MARPAT 134:71905
GI
```

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Indazole derivs. I [A1 and A2 are certain D- or L-amino acid residues which may be substituted; R1 = amino, alkylamino, arylamino, heteroalkyl, etc.; R2, R3 = H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroalkyl, indanyl, etc. or R2R3N = (un)substituted piperidinyl, piperazinyl, morpholino, or pyrrolidinyl; R4 = (un)substituted aryl, arylalkyl, cycloalkyl, heteroaryl; X = O, S; m = 0-3; n = 1 or 2; p = 0 or 1] were prepared as thrombin receptor antagonists for the treatment of diseases associated with thrombosis, restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, atherosclerosis, ischemic conditions, angiogenesis related disorders, cancer, and neurodegenerative disorders. **Thus**, compound II, prepared by a multistep procedure starting from 6-nitroindole (scheme given), showed IC50 = 0.31 and 0.04 µM, resp., in the thrombin-induced gel-filtered platelet aggregation and thrombin receptor binding assays.

IT **315203-31-7P 315203-32-8P 315203-33-9P**
315203-34-0P 315203-35-1P 315203-36-2P
315203-41-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indazole peptidomimetics as thrombin receptor antagonists)

RN 315203-31-7 HCAPLUS

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[(phenylmethyl)amino]carbonyl]propyl]-α-[[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indazol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 315203-32-8 HCAPLUS
CN Benzenepropanamide, N-[(1S)-3-amino-1-[[(phenylmethyl)amino]carbonyl]propyl]-4-chloro-α-[[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indazol-6-yl]amino]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 315203-33-9 HCAPLUS
CN L-Alaninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indazol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 315203-34-0 HCAPLUS
CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(1R)-1-phenylethyl]amino]carbonyl]propyl]-α-[[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indazol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 315203-35-1 HCAPLUS
CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(1S)-2-hydroxy-1-phenylethyl]amino]carbonyl]propyl]-α-[[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indazol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 315203-36-2 HCAPLUS

CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indazol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 315203-41-9 HCAPLUS

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[(phenylmethyl)amino]carbonyl]propyl]-α-[[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indazol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, dihydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

IT 315203-39-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indazole peptidomimetics as thrombin receptor antagonists)

RN 315203-39-5 HCAPLUS

CN 1H-Indazol-6-amine, 1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



L13 ANSWER 15 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:12414 HCAPLUS
DOCUMENT NUMBER: 134:71904
TITLE: Preparation of indole and indazole urea-peptoids as thrombin receptor antagonists
INVENTOR(S): McComsey, David F.; Hoekstra, William J.; Maryanoff, Bruce E.; Zhang, Han-cheng
PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA; Cor Therapeutics, Inc.
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**

```
LANGUAGE:                  English
FAMILY ACC. NUM. COUNT:    2
PATENT INFORMATION:

     PATENT NO.            KIND   DATE        APPLICATION NO.         DATE
     ---------------       ----   --------    --------------------    --------
     WO 2001000576          A1    20010104    WO 2000-US18021         20000629 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
             CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
             ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
             LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
             SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW:  GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
             CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     US 6365617             B1    20020402    US 2000-603229          20000626 <--
PRIORITY APPLN. INFO.:                        US 1999-141555P     P   19990629
                                              US 2000-603229      A   20000626
OTHER SOURCE(S):           MARPAT 134:71904
GI
```



I



II

AB   Indole and indazole urea-peptoid compds. I [R1 = amino, alkylamino, arylamino, heteroalkyl, etc.; R2 = (un)substituted aryl, arylalkyl, cycloalkyl, heteroaryl; R3 = H, alkyl; R4, R5 = H, alkyl, aminoalkyl, aryl, aralkyl, heteroaryl, cycloalkyl, etc.; R6, R7 = H, alkyl, aminoalkyl, aminocycloalkyl, aryl, heteroarylalkyl, etc.; R8 = H, alkyl, aminoalkyl, allyl, cycloalkyl, aryl, heteroaryl, etc.; X = CH, N; n = 0-3; m = 0 or 1; p = 1 or 2] were prepared as thrombin receptor antagonists for the treatment of diseases associated with thrombosis, restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, atherosclerosis, ischemic conditions, angiogenesis related disorders,

cancer, and neurodegenerative disorders. **Thus**, compound II, prepared by a multistep procedure starting from 6-nitroindole (scheme given), showed IC50 = 1.3 and 0.5 M, resp., in the thrombin-induced gel-filtered platelet aggregation and thrombin receptor binding assays.

IT **314751-99-0P 314752-01-7P 314752-07-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indole and indazole urea-peptoids as thrombin receptor antagonists)

RN 314751-99-0 HCAPLUS
CN Glycinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indazol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N2-(2-aminoethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 314752-01-7 HCAPLUS
CN Glycinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indazol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N2-(4-aminobutyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



```
RN   314752-07-3  HCAPLUS
CN   Benzenepropanamide, N-(3-aminopropyl)-α-[[[[1-[(2,6-
     dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indazol-6-
     yl]amino]carbonyl]amino]-3,4-difluoro-, (αS)- (9CI)  (CA INDEX NAME)

Absolute stereochemistry.
```



```
REFERENCE COUNT:          7      THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
                                 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> log y
COST IN U.S. DOLLARS                              SINCE FILE     TOTAL
                                                       ENTRY   SESSION
FULL ESTIMATED COST                                   165.85    502.58

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE     TOTAL
                                                       ENTRY   SESSION
CA SUBSCRIBER PRICE                                   -21.00    -21.00

STN INTERNATIONAL LOGOFF AT 20:51:49 ON 29 JAN 2006
```